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ABSTRACT  
Studies suggest that sleep disturbance may be an important etiological factor in 
the development of comorbid anxiety and depressive disorders, whereby anxiety leads 
to sleep difficulties, which in turn increase the vulnerability for depression. The 
primary aim of this study was to determine whether the sequential comorbidity patterns 
observed at the disorder level (i.e., where anxiety disorders most often precede insomnia, 
and insomnia most often precedes depression) were also present in daily fluctuations of 
symptoms. The secondary aim was to explore possible moderators of any observed 
temporal associations. Participants were 15 patients with generalized anxiety disorder 
(GAD; mean age = 28.9 years, SD = 9.8) and 15 good sleeper controls (mean age = 27.1 
years, SD = 8.3) who were comparable in female:male ratio (73% female vs. 67% 
female). For 14 days, participants wore an actigraph to objectively assess sleep quality 
(sleep onset latency, total sleep time, wake after sleep onset, sleep efficiency) and 
completed daily symptom ratings multiple times each day using their smartphones to 
assess symptoms of anxiety, depressed mood, and subjective sleep quality. 
  
  vii
Study aims were assessed using multilevel modeling, with daily symptoms nested 
within individuals. Many of the analyses were lagged such that the time-varying predictor 
variable preceded the time-varying outcome variable temporally. Consistent with 
hypotheses, results demonstrated that anxious mood was predictive of later subjective and 
objective sleep disturbance in individuals with GAD, and this effect was strongest among 
individuals with higher levels of neuroticism, negative affect, and dysfunctional beliefs 
about sleep. Anxious mood was not associated with later subsequent sleep disturbance in 
healthy controls. In the GAD group, subjective and objective sleep disturbance predicted 
later depressed mood; this effect was moderated by temperament and dysfunctional beliefs 
about sleep. For the control group, the effect of subjective sleep disturbance on later 
depressed mood was moderated by neuroticism and the effect of objective sleep 
disturbance was moderated by dysfunctional beliefs about sleep, suggesting that sleep 
disturbance may increase vulnerability for depressed mood even in healthy individuals. 
These results suggest that explicitly targeting sleep disturbance during the treatment of 
GAD may attenuate the experience of depressive symptoms.  
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Introduction 
Epidemiological studies suggest that approximately 40 million American adults 
currently suffer from an anxiety disorder, with a 12-month prevalence rate of 18.1% and 
a lifetime prevalence rate of 28.8% (Kessler, Chiu, Demler, Merikangas, & Walters, 
2005). Anxiety disorders are the most commonly diagnosed mental disorder, and are 
associated with significant distress and functional impairment in social, occupational, and 
health-related domains, resulting in considerable economic and societal costs each year 
(Aderka et al., 2012; Barrera & Norton, 2009; Whiteford, Ferrari, Degenhardt, Feigin, & 
Vos, 2015). When anxiety is comorbid with a depressive disorder, consequences include 
more severe and persistent symptoms, poorer quality of life, increased economic costs in 
health service utilization and losses in work productivity, greater risk of suicide, and a 
blunted response to treatment (Wittchen, Beesdo, Bittner, & Goodwin, 2003; Wittchen, 
Carter, Pfister, Montgomery, & Kessler, 2000). 
Sleep disturbance is often conceptualized as a symptom of other disorders or as 
secondary to another disorder, particularly anxiety and depressive disorders (Harvey, 
2001; Mason & Harvey, 2014; Reynolds et al., 2010; Stepanski & Rybarczyk, 2006). It is 
often assumed that diagnosis and treatment of the primary disorder or underlying 
psychological disorder will result in the remission of sleep difficulties as well. However, 
in a study where patients with posttraumatic stress disorder (PTSD) were treated with 
cognitive behavioral therapy (CBT) for PTSD, over half of patients continued to report 
symptoms of insomnia after remission of PTSD (Zayfert & DeViva, 2004). Another 
study demonstrated similar findings; following CBT for major depression, 92% of 
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patients who longer met depressive criteria continued to report symptoms of sleep 
disturbance (Carney, Harris, Friedman, & Segal, 2011).  
Prior to a recurrent depressive episode, insomnia and fatigue are the most 
frequently reported symptoms (Perlman, Johnson, & Mellman, 2006), with insomnia 
preceding approximately half of new onset or recurrent depressive episodes (Jackson, 
Cavanagh, & Scott, 2003). Symptoms of insomnia are also the most persistent and 
treatment-resistant symptoms in depression (Israel, 2010; McClintock et al., 2011; 
Nierenberg et al., 2010; Taylor, Walters, Vittengl, Krebaum, & Jarrett, 2010). Among a 
group of patients who met objective criteria for remission of depression, patients who did 
not feel that they had achieved full remission reported distress related to sleep 
disturbance (Zimmerman et al., 2005; 2012), suggesting that sleep disturbance may play 
a significant role in an individual’s subjective perception of functional impairment.   
The emergence of transdiagnostic models of psychopathology, which aim to 
identify common processes or risk factors across multiple forms of psychopathology, 
represent a significant advancement in our understanding of comorbidity across disorders 
(Barlow, Allen, & Choate, 2004; Harvey, Watkins, Mansell, & Shafran, 2004; Hofmann, 
Sawyer, Fang, & Asnaani, 2012). More than half of individuals with one psychological 
disorder meet criteria for at least one other disorder (Kessler et al., 2005), and continued 
exploration of transdiagnostic processes may help us better understand the mechanisms 
that contribute to such high rates of comorbidity. If sleep disturbance mediates the causal 
pathway by which anxiety disorders increase the risk for incident depression, the 
implications for both comorbidity models and clinical practice would be significant. 
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Wittchen and colleagues (2003) estimate that if all anxiety disorders were successfully 
treated in individuals between the ages of 14 and 24, up to 43% of depressive episodes in 
early adulthood would be prevented. Other studies of sequential comorbidity suggest that 
childhood anxiety is a strong predictor of adolescent depression and advocate for further 
exploration of a causal anxiety-depression link (e.g., Schleider, Krause, & Gillham, 2014). 
Concurrent and Sequential Comorbidity of Anxiety and Depression 
Extensive comorbidity also exists between anxiety and depressive disorders. 
Comorbidity patterns assessed in a large sample of treatment-seeking adults using a semi-
structured, diagnostic interview at an anxiety and related disorders clinic indicated that 
over half (63%) of patients with a principal diagnosis of a depressive disorder also 
received a current diagnosis of an anxiety disorder (Brown, Campbell, Lehman, Grisham, 
& Mancill, 2001). In another epidemiological study of over 1,700 adults, 67% of 
individuals with a depressive disorder had a current comorbid anxiety disorder and 63% 
of individuals with an anxiety disorder also met criteria for a current depressive disorder 
(Lamers et al., 2011). Extant studies suggest that comorbid anxiety and depressive 
disorders are associated with greater symptom severity, increased disability, greater 
chronicity, and greater risk of suicide (Bruce et al., 2005; Dolnak, 2006; Hirschfeld, 
2001). Comorbid anxiety and depressive disorders are also associated with the highest 
productivity loss-related costs of all chronic illness, more days spent in bed due to illness, 
poorer performance at work, more somatic complaints, and high utilization of health 
services (Marciniak et al., 2005; McLaughlin, Khandker, Kruzikas, & Tummala, 2006; 
Wittchen, 2002), with GAD resulting in more economic costs than any other anxiety 
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disorder (Bereza, Machado, & Einarson, 2009). Perhaps of particular importance, 
comorbid depression results in poorer treatment outcome for anxiety disorders (Bruce et 
al., 2005; Campbell-Sills et al., 2012; Wittchen, Kessler, Pfister, & Lieb, 2000). The 
same is true in the reverse direction – comorbid anxiety results in a delayed or blunted 
response to both pharmacological (Andreescu et al., 2007; Fava et al., 2004) and 
psychological treatments for depression (Hirschfeld, 2001; Overbeek, Schruers, 
Vermetten, & Griez, 2002; Westen & Morrison, 2001). 
Whereas the concurrent comorbidity of anxiety and depressive disorders is well 
documented (e.g., Burke et al., 2005; Kessler et al., 2005a, 2005b), the data on sequential 
comorbidity (i.e., when one disorder reliably predicts the onset of another disorder) is less 
straightforward due to some evidence of bidirectional relationships. However, both 
longitudinal (e.g., Burke et al., 2005; Merikangas et al., 2003; Wittchen, Kessler, et al., 
2000) and retrospective studies (e.g., de Graaf, Bijl, Spijker, Beekman, & Vollebergh, 
2003; Essau, 2003; Lamers et al., 2011) show that anxiety disorders most often precede 
depression. Indeed, while anxiety disorders are frequently present in the absence of 
depression, depression in the absence of comorbid anxiety is less common (e.g., Almeida 
et al., 2012).  
Temporal Sequence of Anxious and Depressive Mood Symptoms 
 In addition to the high rates of concurrent and sequential comorbidity seen in 
anxiety and depressive disorders, anxiety symptoms are also significantly correlated with 
depressive symptoms, with greater overlap between these constructs observed at the 
symptom level than at syndrome or disorder levels (Hiller, Zaudig, & von Bose, 1989; 
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Preisig, Merikangas, & Angst, 2001). In a recent daily diary study, Starr and Davila 
(2012a) found that anxious and depressed mood were not only concurrently associated, 
but that daily anxious mood predicted later depressed mood; depressed mood did not 
reliably predict later anxious mood. These findings suggest that the temporal precedence 
of anxiety disorders over depression that has been observed both longitudinally and 
retrospectively may also present at the symptom level and over much shorter periods of 
time. 
 Given the temporal precedence of anxiety over depression at both the symptom 
and disorder level, it has been proposed that anxiety may serve as a risk factor for 
depression (e.g., Wittchen et al., 2003). Whether anxiety disorders truly represent a 
causal pathway by which vulnerability for depression develops requires further 
investigation, but a few studies have begun to explore the role of various transdiagnostic 
processes that may mediate the temporal precedence of anxiety over depression. In a 
prospective study that assessed undergraduate students over two time points, Grant and 
colleagues (2007) found that social anxiety at intake was associated with emotional 
avoidance, which predicted depressive symptoms one year later, even after controlling 
for depressive symptoms present at intake. Among a sample of treatment-seeking socially 
anxious adults, behavioral avoidance was shown to account for 41.9% of the effect of 
social anxiety symptoms on depressive symptoms at baseline, and changes in behavioral 
avoidance during treatment were significantly related to subsequent changes in 
depressive symptoms (Moitra, Herbert, & Forman, 2008). In a daily diary study of 
patients with GAD, daily cognitions about anxious mood (i.e., rumination about anxiety 
 6 
symptoms, negative attributions about anxiety symptoms) moderated the concurrent 
association of daily anxious and depressed mood, such that anxious and depressed mood 
were more likely to co-occur on days when patients engaged in rumination or viewed 
their anxiety symptoms as more difficult to control (Starr & Davila, 2012b). 
 Before the temporal sequencing of anxiety and depression can be conceptually 
integrated into existing comorbidity models and used to inform treatment approaches, 
further research is needed on the mechanisms by which these temporal patterns occur. 
There is currently a discrepancy between the processes that have been hypothesized to 
mediate the relationship between anxiety and depression, and the methodology used to 
assess these relationships. Most of the proposed mediators discussed above (e.g., 
emotional avoidance, rumination, behavioral avoidance) are processes that occur over the 
course of very short time intervals (i.e., days or weeks), yet longitudinal studies of 
sequential comorbidity often involve annual assessments over the course of multiple 
years (e.g., Burke et al., 2005; Wittchen et al., 2003). Indeed, Mineka, Watson, and Clark 
(1998) proposed that the study of anxiety-depression comorbidity should begin with 
exploration of the co-occurrence of the symptoms that define the disorders. By evaluating 
mediators of daily symptom co-occurrence, we may be able to gain a more refined 
understanding of the microprocesses involved in the presentation of concurrent anxiety 
and depression, which may lead to more macro-level changes in our conceptualization of 
their comorbidity (Starr & Davila, 2012a).  
Sleep Disturbance as a Transdiagnostic Process in Anxiety and Depression 
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Sleep disturbance is highly comorbid across many disorders and is consistently 
recognized as a core symptom in anxiety and depressive disorders (Buckner, Bernert, 
Cromer, Joiner, & Schmidt, 2008; Dolsen, Asarnow, & Harvey, 2014; Peterson & Benca, 
2006). Up to 70% of patients with depression report experiencing sleep disturbance (e.g., 
insomnia, hypersomnia) that persists even in periods of remission and is associated with 
poorer treatment outcome (Medina, Lechuga, Escandon, & Moctezuma, 2014; Murphy & 
Peterson, 2015; Plante, 2015). Individuals with anxiety disorders commonly report sleep 
disturbance, including insomnia, nonrestorative sleep, and excessive daytime fatigue, that 
appears to exacerbate symptom severity (Cox & Olatunji, 2016). Comorbid anxiety and 
depression are associated with more severe insomnia complaints than depressive or 
anxiety disorders alone, and individuals with anxiety or depression and clinical levels of 
insomnia report more severe symptoms of anxiety, depression, and disability than those 
without insomnia (Mason & Harvey, 2014; Soehner & Harvey, 2012; Soehner, Kaplan, & 
Harvey, 2014). 
Temporal sequencing of anxiety disorders, depression, and insomnia suggest that 
anxiety disorders most often precede insomnia, while insomnia tends to precede 
depression. In a retrospective study exploring the direction of risk between these 
constructs, Johnson and colleagues (2006) found that anxiety disorders preceded 
insomnia 73% of the time, while insomnia preceded the development of depression in 
69% of cases; prior insomnia was not associated with the onset of anxiety disorders and 
prior depression was not associated with the onset of insomnia. The presence of any 
anxiety disorder was associated with increased risk of subsequent insomnia (OR: 3.5), 
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and prior insomnia was associated with onset of depression (OR: 3.8), even after 
adjusting for any prior anxiety disorders (Johnson et al., 2006). Other epidemiological 
studies of insomnia suggest that individuals presenting with symptoms of insomnia are 
between 2.6 (Baglioni et al., 2011) and 9.8 times (Taylor, Lichstein, Durrence, Reidel, & 
Bush, 2005) more likely to develop depression than those without insomnia. Longitudinal 
studies demonstrate a similar relationship between anxiety disorders, insomnia, and 
depression (e.g., Jansson & Linton, 2006; Jansson-Frojmark & Lindblom, 2008). Taken 
together, these studies suggest that sleep disturbance may be an important etiological 
factor in the development of comorbid anxiety and depressive disorders, whereby anxiety 
leads to sleep difficulties, which in turn increase the vulnerability for depression.  
The Role of Sleep Disturbance in Daily Anxious and Depressed Mood 
 There is evidence to suggest that even short-term manipulation of sleep impacts 
mood symptoms the next day. For example, sleep loss has been shown to both amplify 
negative emotions in response to disruptive events and to reduce positive emotions in 
response to goal-enhancing events experienced the following day in medical school 
residents (Zohar, Tzischinsky, Epstein, & Lavie, 2005). Healthy adults allowed only 4.5 
hours in bed report more sleepiness and greater symptoms of depression than those who 
spent 7.5 hours in bed (De Valck & Cluydts, 2001). Following 35 hours of sleep 
deprivation, healthy adults demonstrate amplified amygdala reactivity to emotionally 
negative stimuli, suggesting that even acute sleep deprivation can result in poor emotion 
regulation the following day (Yoo, Gujar, Hu, Jolesz, & Walker, 2007). In an experience 
sampling study, poor subjective sleep quality predicted low positive affect and subjective 
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daytime dysfunction the next day in both patients with clinical levels of depression and 
healthy controls (Bower, Bylsma, Morris, & Rottenberg, 2010). In patients with bipolar 
disorder, the amount of time spent awake after sleep onset has been shown to predict 
negative mood the next morning (Talbot et al., 2012). These studies propose that 
disturbances in sleep quality, either subjectively reported or experimentally manipulated, 
result in reduced pleasurable experiences the following day, which over time may result 
in an increased risk for depression.  
 While it is more difficult to experimentally manipulate daily anxiety symptoms to 
assess the acute impact on sleep quality, some studies have explored the effects of 
cognitive arousal on sleep onset latency. Tang and Harvey (2004) randomized good 
sleeper controls to either an anxious cognitive arousal, neutral cognitive arousal, or a no 
manipulation condition prior to napping, and found that individuals in both arousal 
conditions overestimated their sleep onset latency compared to individuals in the no 
manipulation condition (i.e., they reported greater sleep onset latency that was not 
associated with objective sleep-onset delay as assessed by actigraphy). Another study 
found that worrying about the anticipated consequences of poor sleep before bed was the 
strongest predictor of delayed sleep onset measured with actigraphy (Wicklow & Espie, 
2000). Unsurprisingly, individuals high in trait rumination tend to experience the most 
sleep interference when instructed to ruminate following a stressful life event (Guastella 
& Moulds, 2007).  
In a sample of healthy controls, variability in sleep timing perceptions was most 
closely related to current symptoms of anxiety, whereas sleep satisfaction perceptions 
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demonstrated the strongest relationships with depression (Mayers, Grabau, Campbell, & 
Baldwin, 2009). In a comparison of patients with major depressive disorder and healthy 
controls, depressed patients reported poorer quality of life, poorer sleep quality, and 
lower mood, despite comparable sleep quality to healthy controls (Mayers, van Hooff, & 
Baldwin, 2003). It is particularly noteworthy that the presence of depressed mood exerted 
the strongest influence on sleep satisfaction in the presence of co-occurring anxiety, even 
though the symptoms of depression were sub-threshold (Mayers et al., 2009), implicating 
a unique interaction between symptoms of anxiety, depression, and sleep disturbance. 
These studies suggest that processes that contribute to the onset and maintenance of 
anxiety disorders (e.g., rumination or excessive worry, safety behaviors) may also 
contribute to sleep difficulties, which result in low mood and daytime dysfunction the 
following day. However, it remains unclear whether actual sleep disturbance (i.e., 
objectively measured sleep parameters) or perceived sleep disturbance, or a combination 
of both, is most strongly related to low mood and daytime dysfunction the following day.  
Rationale for the Proposed Study  
GAD is the anxiety disorder most strongly associated with depression (Kessler et 
al., 2005b; Wittchen et al., 2003). GAD is also one of only two anxiety disorders where 
sleep difficulty is explicitly recognized as a diagnostic criterion (American Psychiatric 
Association, 2013). Among individuals with insomnia and comorbid anxiety disorders, 
GAD is the most commonly reported anxiety disorder in both primary care patients 
(Marcks, Weisberg, Edelen, & Keller, 2010) and community samples (Ramsawh, Stein, 
Belik, Jacobi, & Sareen, 2009). Patients with GAD report decreased total sleep time, 
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poorer sleep efficiency, and more frequent early morning awakenings (Guille, Cortese, & 
Uhde, 2012). Across six different polysomnography studies, a diagnosis of GAD was 
associated with an average of 32.8 more minutes spent awake after falling asleep and a 
decrease of 54.8 minutes in total sleep time (Monti & Monti, 2000).  
While all anxiety disorders share commonalities with one another and high rates 
of comorbidity with depression, it is certainly possible that different causal pathways are 
associated with different anxiety disorders. Research on temporal sequencing of 
symptoms within disorders is exceptionally rare, and the relationship between nightly 
sleep difficulties and daily symptoms of anxious and depressed mood has yet to be 
systematically evaluated. Given that there is already preliminary evidence that daily 
anxious mood predicts later depressed mood in patients with GAD and a history of 
depressive symptoms (Starr & Davila, 2012a), exploring the relationship between 
anxiety, depressed mood, and sleep disturbance in a analogous sample (i.e., patients with 
GAD and a history of depressive symptoms) is a reasonable starting point. 
Proposed Moderators 
 As discussed earlier, a few studies have begun to explore possible moderators of 
the comorbidity between anxiety and depressive disorders, including rumination 
(McEvoy, Watson, Watkins, & Nathan, 2013; Spinhoven, Drost, van Hemert, & Penninx, 
2015; Starr & Davila, 2012a) and behavioral avoidance (Moitra et al., 2008). Exploring 
potential moderators of the functional relationships between anxiety, sleep disturbance, 
and depressed mood at the within-subject level is important because it may shed greater 
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light on the co-occurrence of these symptoms, particularly with regard to markers of 
vulnerability for symptom co-occurrence and the identification of treatment targets.  
 One proposed moderator of the relationship between sleep disturbance and 
anxiety and depressive disorders is the presence of faulty sleep-related cognitions (i.e., 
maladaptive beliefs and appraisals about sleep, unrealistic expectations). Dysfunctional 
beliefs about sleep are considered a perpetuating factor in the cognitive model of 
insomnia (Harvey, 2002a), and have demonstrated significant relationships with 
subjective report of insomnia symptoms, anxiety, and depression, but not with specific 
sleep parameters (i.e., sleep diary data or polysomnography) or specific insomnia 
subtypes (Carney et al., 2010a; Morin, Vallieres, & Ivers, 2007; Park, An, Jang, & 
Chung, 2012). High levels of maladaptive beliefs about sleep have been shown to 
differentiate between individuals with insomnia and individuals with either depression or 
comorbid insomnia and depression, with much of the variability in dysfunctional beliefs 
accounted for by depression severity (Carney, Edinger, Manber, Garson, & Segal, 2007). 
These studies suggest that dysfunctional beliefs about sleep may represent a salient 
treatment target for indiviudals with anxiety or depression who are also reporting sleep 
disturbance.  
 Another perpetuating factor in insomnia is the presence of sleep-related safety 
behaviors (Harvey, 2002a, 2002b); examples include attempts to catch up on sleep by 
napping, going to bed early, or conserving energy during the day (Ree & Harvey, 2004). 
Safety behaviors, which are strategies employed to prevent the occurrence of a feared 
outcome, are seen in psychological disorders, particularly in individuals with anxiety 
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disorders. Safety behaviors contribute to the maintenance of symptoms because they 
prevent disconfirmation of maladaptive beliefs (Salkovskis, 1991). Sleep-related safety 
behaviors are associated with both sleep disturbance and daytime dysfunction, and have 
been shown to mediate the efficacy of CBT for insomnia (Lancee, Eisma, van Straten, & 
Kamphuis, 2015). In an outpatient sample of adults with anxiety and depressive 
disorders, sleep-related safety behaviors were strongly associated with subjective reports 
of sleep disturbance and fatigue (Fairholme & Manber, 2014). There is also evidence that 
individuals with higher levels of depression tend to report greater utilization of sleep-
related safety behaviors (Woodley & Smith, 2006), again suggesting that safety behaviors 
related to sleep influence symptoms of sleep disturbance in individuals with anxiety or 
depression.  
 While maladaptive beliefs about sleep and sleep-related safety behaviors 
represent specific cognitive and behavioral processes that may influence the functional 
relationship between anxiety, sleep disturbance, and depressed mood, more generalized 
vulnerabilities may also contribute to the co-occurrence of these symptoms. Neuroticism 
is a temperamental style associated with an enduring tendency to experience negative 
emotions, and appears to be a generalized biological vulnerability to experience anxiety 
or depression (Barlow, Sauer-Zavala, Carl, Bullis, & Ellard, 2014). There is also 
evidence to suggest that individuals higher in neuroticism are more predisposed to 
experience sleep disturbance (Duggan, Friedman, McDevitt, & Mednick, 2014; Gurtman, 
McNicol, & McGillivray, 2014). In an undergraduate sample, anxiety sensitivity, 
dysfunctional beliefs about sleep, and neuroticism were all significantly related to sleep 
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disturbance, but neuroticism emerged as the most significant predictor in a stepwise 
regression (Calkins, Hearon, Capozzoli, & Otto, 2013). A longitudinal study that 
followed participants from birth to midlife found that although neuroticism assessed in 
adolescence did not predict the onset of sleep difficulties, sleep difficulties in adolescence 
and into young adulthood predicted midlife neuroticism levels and continued sleep 
difficulties (Danielsson, Jansson-Frojmark, Linton, Jutengren, & Stattin, 2010). Despite 
ample empirical evidence supporting the contribution of neuroticism as a generalized 
biological vulnerability to emotional disorders, very few studies to date have explored the 
contribution of neuroticism to sleep difficulties, and the vast majority of existing studies 
have relied on cross-sectional or retrospective data. 
Hypotheses 
The current study aimed to determine whether the sequential comorbidity patterns 
observed at the disorder-level are also present at the symptom-level, as well as to explore 
possible moderators of this relationship, which would not only provide support for the 
inclusion of sleep disturbance as an explicit target in existing treatment protocols, but 
also inform approaches for addressing sleep disturbance from a prevention framework.  
Aim 1. To examine the temporal associations among anxiety, sleep disturbance, 
and depressed mood as assessed by daily symptom ratings and actigraphy over a 
monitoring period of 14 days. 
Hypothesis 1.1. Anxiety at t-1 will be significantly related to prospective sleep 
disturbance at t as assessed by daily symptom ratings and actigraphy. 
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Hypothesis 1.2. Sleep disturbance at t-1 will be significantly related to depressed 
mood at t as assessed by daily symptom ratings during the following day. 
Aim 2. To examine potential moderators of any temporal associations among 
daily symptoms of anxiety, sleep disturbance, and depressed mood.  
Hypothesis 2.1. Dysfunctional beliefs about sleep will predict stronger 
associations among anxiety, sleep disturbance, and depressed mood.  
Hypothesis 2.2. Sleep-related safety behaviors will predict stronger associations 
among anxiety, sleep disturbance, and depressed mood. 
Hypothesis 2.3. Neuroticism and negative affect will predict stronger associations 
among anxiety, sleep disturbance, and depressed mood. 
Methods 
Participants 
 Participants for the current study consisted of a clinical sample of adults between 
the ages of 18 and 65 with a principal diagnosis of GAD and a history of depressive 
symptoms, and a control sample of good sleeper, healthy subjects. A total of 33 
participants were enrolled in the study to obtain sufficient data for 30 participants (15 
healthy controls, 15 patients with GAD). Recruitment flow is presented in Figure 1 and 
Figure 2 for the control and clinical samples, respectively. Individuals for the clinical 
sample were recruited through the Center for Anxiety and Related Disorders (CARD) and 
healthy control participants were recruited through the community via online 
advertisements. Participants recruited through CARD were treatment-seeking adults who 
completed a diagnostic assessment as part of routine Center practices.  
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Exclusion criteria for all participants included: 1) inability to speak and 
understand English; 2) inability or unwillingness to provide informed consent; 3) serious 
medical illness for which hospitalization may be likely within the next three months; 4) 
active suicidal or homicidal ideation, or suicide attempts within the past six months 
requiring hospitalization; 5) history of serious head injury or unexplained loss of 
consciousness; 6) seizure disorder; 7) use of prescription sleep medications (e.g., Lunesta, 
Ambien), anxiolytics used as sleep aids (e.g., Ativan) or dependence on over-the-counter 
sleep aids (e.g., Tylenol PM, Benadryl, ZzzQuil, melatonin dietary supplements); 8) 
unwillingness to maintain stable medication dosage throughout 14-day monitoring 
period; 9) coffee consumption (or equivalent) of  > four cups in a 24 hour period for the 
duration of the 14-day monitoring period; and 10) alcohol consumption of  >14 drinks 
per week for the duration of the 14-day monitoring period. Participants were asked to 
abstain from marijuana use for the duration of the 14-day monitoring period, minimize 
caffeine intake after 4:00 PM, and to avoid consuming alcohol within two hours of 
bedtime.  
The following additional exclusion criteria applied to healthy participants: 1) any 
current depressive disorder, including seasonal major depressive episodes, anxiety 
disorder, obsessive-compulsive or related disorder, trauma- or stressor-related disorder, 
somatic symptom or related disorder, and substance-related or addictive disorders, or 
schizophrenia spectrum or other psychotic disorder; 2) total score of 5 or greater on the 
insomnia screening measure; and 3) current symptoms consistent with diagnosis of sleep 
disorder. The following additional exclusion criteria applied to participants with GAD: 1) 
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schizophrenia spectrum or other psychotic disorder, bipolar or related disorder, mental 
disorder due to a general medical condition or substance; 2) no hospitalization for 
depression within the past year; and 3) current symptoms consistent with diagnosis of 
sleep disorder other than insomnia. In addition, participants with GAD had to endorse a 
history of at least one of the two cardinal symptoms of depression (i.e., significant 
depressed mood or loss of interest in almost all usual activities). They were also required 
to meet the following stabilization criteria for psychotropic medications: 1) six weeks for 
initiation or dosage change and four weeks for discontinuation of antidepressants or 
stimulants; and 2) four weeks for initiation and two weeks for dosage change or 
discontinuation of benzodiazepines or beta-blockers. Comorbid, current diagnoses of 
major depression, persistent depressive disorder, or any anxiety disorder were permitted 
as long as GAD was the principal diagnosis.  
Measures 
Diagnostic Assessment 
After obtaining informed consent, the following measures were administered to 
determine study eligibility. 
Anxiety and Related Disorders Schedule for DSM-5: Lifetime version  
(ADIS-5-L; Brown & Barlow, 2014). The ADIS5-L is a semi-structured interview 
designed to assess for DSM-5 diagnoses of anxiety disorders, obsessive-compulsive and 
related disorders, trauma- and stressor-related disorders, depressive disorders, somatic 
symptom and related disorders, and substance-related and addictive disorders. The 
investigator administered a modified version of the ADIS-5 that assessed for current 
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diagnoses to patients and healthy controls, unless a patient had already undergone the 
diagnostic assessment through CARD. The ADIS-5 allowed the investigator to assess all 
diagnostic inclusion and exclusion criteria for both GAD patients and healthy controls.  
Insomnia Severity Index (ISI; Bastien, Vallieres, & Morin, 2001). The ISI is a 7-
item self-report instrument that measures sleep impairment, distress, and daytime 
impairment. ISI scores converge closely with polysomnography and are frequently used 
as a screening tool or outcome measure in behavioral sleep medicine. A clinical cut-off 
score of 10 was determined to be optimal for the detection of significant insomnia 
symptoms in a community sample (Morin, Belleville, Belanger, & Ivers, 2011).  
 Sleep Disorder Assessment. The Sleep Disorder Assessment is a 38-item self-
report measure designed to quickly and efficiently screen for the presence of sleep 
disorders, including sleep apnea, insomnia, narcolepsy, gastroesophageal reflux, and 
periodic limb movement disorder.  
Self-Report Measures 
Dysfunctional Beliefs and Attitudes about Sleep Scale, Brief Version (DBAS-
16; Morin et al., 2007). The DBAS-16 is a 16-item self-report measure of sleep-related 
beliefs comprised of four factors: medication, worry/helplessness about insomnia, 
expectations for sleep, and perceived consequences of insomnia. The DBAS-16 has 
demonstrated acceptable internal consistency and temporal stability.  
Pittsburgh Sleep Quality Index (PSQI; Buysse, Reynolds, Monk, Berman, & 
Kupfer, 1989). The PSQI is a 19-item self-report measure designed to assess sleep quality 
and disturbances in a clinical population retrospectively over the past month. It yields one 
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global score and seven component scores: sleep latency, subjective sleep quality, sleep 
duration, habitual sleep efficiency, use of sleeping medication, sleep disturbances, and 
daytime dysfunction. The PSQI has demonstrated adequate internal consistency and 
construct validity (Carpenter & Andrykowski, 1998).  
Sleep-Related Behaviours Questionnaire (SRBQ; Ree & Harvey, 2004). The 
SRBQ is a 32-item self-report measure that assesses the use of behavioral strategies used 
to cope with daytime fatigue and to improve sleep. The SRBQ has demonstrated strong 
reliability and has been shown to successfully differentiate between poor and good 
sleepers (Ree & Harvey, 2004).  
Fatigue Severity Scale (FSS; Krupp, LaRocca, Muir-Nash, & Steinberg, 1989). 
The FSS is a 9-item self-report measure of perceived fatigue severity and associated 
interference. It is the most commonly used fatigue specific questionnaire (Hjollund, 
Andersen, & Bech, 2007), and has demonstrated excellent internal consistency and 
reliability (Valko, Bassetti, Bloch, Held, & Baumann, 2008). 
Sleep Habits and Hygiene Checklist (SHHC). The SHHC is an unpublished 
self-report checklist designed to assess the frequency with which an individuals engages 
in poor sleep hygiene behaviors (e.g., daytime napping, watching television in bed).  
The Morningness-Eveningness Composite Scale (MECS; Horne & Ostberg, 
1976). The MECS is a brief, 13-item self-report measure designed to assess individual 
variability in preferences for morning or evening activities (i.e., morning and evening 
chronotypes). Evening chronotypes have demonstrated stronger relationships with 
depression severity and sleep variability than morning chronotypes (Suh et al., 2012).  
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Beck Anxiety Inventory (BAI; Beck & Steer, 1990). The BAI is a 21-item, brief 
self-report inventory that measures the severity of anxiety symptoms and it is has 
demonstrated strong psychometric validity and reliability. The BAI is especially effective 
for differentiating between symptoms of anxiety and depression.  
Beck Depression Inventory-II (BDI-II; Beck, Steer, & Brown, 1996). The BDI 
is a 21-item self-report inventory that measures the severity of depressive symptoms and 
it has shown good convergent and discriminant validity, and high internal consistency 
(Coles, Gibb, & Heimberg, 2001). 
Penn State Worry Questionnaire (PSWQ; Meyer, Miller, Metzger, & Borkovec, 
1990). The PSWQ is a 16-item measure designed to assess the trait of worry. It has been 
shown to differentiate between GAD-diagnosed clinical subjects and healthy controls, 
and between GAD and other anxiety disorders (Brown, Antony, & Barlow, 1992).  
Work and Social Adjustment Scale (WSAS; Marks, Connolly, & Hallam, 1973; 
Mundt, Marks, Shear, & Greist, 2002). The WSAS is a 5-item self-report measure of 
symptom interference in the domains of work, home management, private leisure, social 
leisure, and family relationships. 
Positive Affect and Negative Affect Scale (PANAS; Watson, Clark, & Tellegen, 
1988). The PANAS is a self-report measure comprised of two 10-item mood scales that 
assess positive and negative affectivity. The scales have demonstrated adequate internal 
consistency and stability over a two-month period.  
Anxiety Sensitivity Index (ASI; Peterson & Reiss, 1992). The ASI is a 16-item 
self-report measure designed to assess fear of anxiety-related sensations, which consists 
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of three lower-order factors: fear of physical symptoms, mental incapacitation, and social 
concerns (Rodriguez, Bruce, Pagano, Spencer, & Keller, 2004). The ASI has 
demonstrated strong internal consistency (Peterson & Reiss, 1992) and discriminant 
validity with measures of trait anxiety (Sandin, Chorot, & McNally, 2001). 
Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-
LES-Q-SF; Endicott, Nee, Harrison, & Blumenthal, 1993). The Q-LES-Q is a brief, 15-
item measure designed to assess enjoyment and satisfaction in a number of life domains. 
It is one of the most commonly used outcomes measures in psychological research and 
has demonstrated good internal consistency, test-retest reliability, and validity 
(Stevanovic, 2011). 
State-Trait Anxiety Inventory, Trait Version (STAI-T; Spielberger, Gorsuch, 
Lushene, Vagg, & Jacobs, 1983). The STAI-T is a 20-item self-report measure that 
assesses more stable, trait-level anxiety using a 4-point Likert scale. The STAI-T is the 
most widely used self-report measure of anxiety and has well-supported construct and 
concurrent validity (Spielberger, 1989).  
NEO Five-Factor Inventory (NFFI; Costa & McCrae, 1992). The NFFI is a 60-
item self-report measure of the five-factor model of personality. Only the 12-item 
Neuroticism scale will be administered, and it will be used to assess levels of neuroticism, 
which have been linked to sleep disturbance (Danielsson et al., 2010; Duggan et al., 
2014; Gurtman et al., 2014). 
Weekly Stress Inventory, Short Form (WSI-SF; Brantley et al., 2007). The 
WSI-SF is a 25-item self-report scale designed to measure minor stressors. Participants 
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rank items on an 8-point Likert scale to indicate whether a particular stressful event 
occurred within the past week, and if so, how much distress it caused; the WSI-SF yields 
an event score (i.e., occurrence) and an impact score (i.e., associated distress). The WSI-
SF has demonstrated good internal consistency for both scores (Brantley et al., 2007). 
The WSI-SF will be administered at baseline, the end of week 1, and the end of week 2 to 
capture psychosocial stressors experienced during the past week. 
Daily Symptom Ratings 
 Daily symptom ratings were completed using ecological momentary assessment 
(EMA), which is an alternative to retrospective self-report assessment, that collects data 
in real-time, in real-world settings, and typically across multiple repeated time points 
(Shiffman, Stone, & Hufford, 2008; Trull & Ebner-Priemer, 2009). EMA is particularly 
well suited to capture data on individual differences, relationships between multiple 
factors, and how these relationships change over time (Shiffman et al., 2008). Participants 
were prompted to provide symptom ratings six times a day (i.e., upon awakening, mid-
morning, noon, mid-afternoon, evening, prior to bedtime); prompts were programmed 
based on the participant’s typical bedtime and wakeup times. The remaining four ratings 
were delivered at regular intervals throughout the day.  
 In order to facilitate compliance with daily symptom ratings, questions were 
designed to assess the relevant variables quickly and efficiently. Based on previous daily 
diary studies (e.g., Starr & Davila, 2012a, 2012b), brief, face-valid items (e.g., “How 
(anxious/depressed] do you feel right now?”) were used to assess anxious and depressed 
mood on a 10-point Likert scale (1 = not at all, 10 = extremely). In order to capture both 
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cardinal symptoms of depression (i.e., low mood, anhedonia), participants were also 
asked once at the end of the day whether they experienced diminished interested or 
pleasure in the activities they usually enjoy.  
Subjective Sleep Measures 
 Subjective sleep quality was assessed using items from the Consensus Sleep 
Diary (CSD; Carney et al., 2012). The CSD is a standardized sleep diary that assesses the 
time of getting into bed, the time at which the participant attempted to fall asleep, sleep 
onset latency, number and duration of awakenings, time of final awakening, final rise 
time, and perceived sleep quality. It also includes items to be completed in the evening, 
including napping or use of alcohol, caffeine, or medications.  
Daytime dysfunction related to sleep difficulty was assessed using the Daytime 
Insomnia Symptom Scale (DISS; Buysse et al., 2007). The DISS is a 20-item self-report 
measure that assesses symptoms of daytime dysfunction related to insomnia, and yields 
four principal component scores: alert/cognition, negative mood, positive mood, and 
sleepiness/fatigue. The DISS was designed and piloted using EMA, and thus was 
appropriate for the aims of the current study.  
Objective Sleep Measures 
Participants wore an actigraph, the Actiwatch 2, continuously on the wrist of the 
non-dominant hand during the 14-day period. Actigraphy is a relatively non-invasive 
method for the monitoring of sleep/wake cycles. Actigraphs resemble wristwatches and 
are water-resistant to allow for continuous use for weeks at a time. Most research 
supports actigraphy as highly appropriate for the assessment of sleep variability from 
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night-to-night in patients with insomnia (e.g., Ancoli-Israel et al., 2003). Activity data 
were sampled in 30-second epochs using a medium wake threshold selection and 
analyzed with the Actiware software program. Participants were instructed to press an 
event marker button to signify when they began trying to fall asleep and when they 
awoke for the final time in the morning. In the absence of event markers, daily sleep 
diary data were utilized to determine the start and end of each rest interval. Each 
actigraphy record was visually inspected to ensure that participants’ reported bed and rise 
times were consistent with observed activity and ambient light patterns. Using these 
parameters, the Actiware software provided ratings of sleep onset latency, total sleep time, 
and wake after sleep onset. Sleep efficiency was calculated using total sleep time and 
time spent in bed.  
Procedure 
Potential participants completed a brief phone screen to determine preliminary 
eligibility criteria as reflected by the inclusion and exclusion criteria listed above. 
Participants received an overview of study procedures, including length of monitoring 
period (14 days), use of an actigraph to monitor sleep, and daily symptom ratings. 
Participants who met preliminary eligibility criteria were then scheduled for an 
enrollment appointment (Study Visit 1).  
For GAD patients referred through CARD, Study Visit 1 was approximately 45 
minutes to one hour. Participants then completed a measure of insomnia symptom 
severity to ensure that sufficient sleep interference was present, as well as a screening 
measure to determine whether a sleep disorder may be present. Study Visit 1 for healthy 
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controls lasted approximately 90 minutes due the administration of a semi-structured 
diagnostic interview in addition to the sleep-related screening measures. All participants 
completed a self-report battery and then were oriented to the actigraph. Next, participants 
downloaded the SymTrend application and were instructed how to use the application to 
complete daily symptom ratings on their smartphones. Participants were given a choice 
between completing the daily symptom ratings on their own smartphone or a smartphone 
provided by the study.  
Following completion of the 14-day monitoring period, participants were 
scheduled to return to the Center for Study Visit 2, which lasted approximately 15 
minutes. During Study Visit 2, participants returned the actigraph and smartphone if 
applicable and were given an opportunity to report any deviations from the study protocol. 
Study adherence data were reviewed with each participant and a preferred mailing 
address for receipt of payment was obtained. Participants were compensated $15 for each 
day where compliance with symptom ratings reaches or exceeds 85% for a maximum 
compensation of $210. All participants provided written informed consent and all study 
procedures were approved by the Institutional Review Board at Boston University.  
Results 
Adherence to Daily Symptom Ratings  
 Participants were prompted via text message or email to complete symptom 
ratings at six points throughout the day: morning, mid-morning, lunch, afternoon, 
evening, and bedtime. At each of these time points, participants were asked to complete 
the daily symptom ratings (i.e., the DISS and single-item, face-valid measures of anxiety 
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and depression), which consisted of 22 items. At bedtime, the daily symptom ratings 
included two additional questions that assessed 1) level of anhedonia experienced over 
the course of the day, and 2) participants’ rating of how much the prior evening’s sleep 
interfered with their functioning over the course of the day. Participants were also 
prompted to complete the morning and evening sleep diaries upon awakening and prior to 
bed, respectively. Therefore, adherence was calculated based on completion of eight 
questionnaires throughout the day and 112 questionnaires over the course of 14-day study. 
Participants completed, on average, 93.24% (SD = 7.72, range = 62 – 100) of the daily 
symptom ratings and earned an average of $191.50 (SD = 28.32, range = 75 – 210) of the 
$210 maximum compensation. There were no differences between the clinical sample 
and healthy controls on adherence to daily symptom ratings or amount of compensation 
received.  
Demographic and Clinical Data 
 Demographic information is presented for each sample in Table 1. The average 
age of participants, collapsed across groups was 28.00 years (SD = 8.97, range = 18 – 53). 
Both groups were primarily female (n = 21), Caucasian (n = 22), and single (n = 22). 
Participants were well educated, with the vast majority completing at least some college 
education (n = 28). There were no significant differences between groups on any of the 
demographic variables, although the relationships between group condition and both 
marital status (χ2 = 10.91, p = .012) and level of education (χ2 = 12.80, p = .012) 
approached statistical significance.  
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 Clinical characteristics of each sample are presented in Table 2. For the clinical 
sample, the average clinical severity rating (CSR) for the principal diagnosis of GAD was 
5.27 (SD = .80, range = 4 - 7) and participants had an average of 1.2 additional diagnoses 
(SD = .86, range = 0 - 2). The three most common comorbid diagnoses were social 
anxiety disorder (n = 5), persistent depressive disorder (n = 5), and major depressive 
disorder (n = 2), with approximately half (46.7%) of the participants meeting criteria for 
an additional current diagnosis of a depressive disorder (i.e., major depressive disorder, 
persistent depressive disorder). Consequently, although a principal diagnosis of GAD was 
a primary inclusion criterion for the study, the clinical sample contained diagnostic 
heterogeneity that paralleled the comorbidity patterns typically observed in patients with 
GAD (e.g., Kessler at al., 2005). 
Only two participants from the GAD sample were on psychotropic medication; 
both participants were prescribed stimulants. The clinical sample reported symptoms 
consistent with moderate levels of depression, anxiety, and anxiety sensitivity, as well as 
severe pathological worry and trait anxiety. Levels of negative affect were similar to 
reported norms for psychiatric samples, but levels of positive affect were over a full 
standard deviation lower than published psychiatric norms (e.g., Clark & Watson, 1991). 
As expected, participants in the clinical sample scored significantly higher than healthy 
controls across all measures of depression, anxiety, and functional impairment. 
Sleep data for each sample are presented in Table 3. On the screening measure of 
insomnia severity (ISI), more than half of GAD participants (n = 9) reported moderate (or 
more severe) difficulty with sleep onset latency, the majority (n = 13) endorsed difficulty 
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with sleep maintenance, and approximately half (n = 8) reported regularly waking up 
earlier than intended. Global scores on the PSQI, a measure of subjective sleep quality, 
were well over the clinical threshold of 5 (M = 10.67, SD = 1.88) for GAD participants. 
Across each of the PSQI component scores, the GAD sample reported significantly 
greater impairment than healthy controls. Average scores for perceived daytime fatigue 
(FSS; mean = 41.40, SD = 10.25) were also elevated above the suggested clinical 
threshold of 36. Participants in the clinical sample reported average levels of 
dysfunctional beliefs about sleep (DBAS) and sleep-related safety behaviors (SRBQ) that 
were comparable to those observed in insomnia samples. Compared to the control group, 
participants with GAD endorsed engaging in more behaviors associated with poor sleep 
hygiene and engaging in those behaviors more frequently within the past month. Across 
both groups, the majority of participants (n = 26) identified as intermediate type, which 
reflects a circadian typology that is neither morning- nor evening-dominant.   
Daily Symptom Ratings 
 Table 4 presents the daily averages of each group for each subscale of the DISS 
(alert/cognition, sleepiness/fatigue, positive mood, negative mood) and the face-valid 
items (e.g., “How (anxious/depressed] do you feel right now?”), as well as the end-of-day 
questions that assessed experience of anhedonia and the degree to which the previous 
evening’s sleep interfered with functioning throughout the day. As expected, the GAD 
sample reported significantly greater levels of daily negative mood, anxiety, depression, 
anhedonia, daytime fatigue, and sleep-related interference than the control group. GAD 
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participants also reported significantly lower levels of daily positive mood and alertness 
compared to healthy controls.  
Sleep Disturbance 
 Table 5 presents the averages for the daily self-reported ratings of sleep 
disturbance and actigraphy outcomes across the 14-day study by group. Consistent with 
expectations, the GAD sample reported poorer quality of sleep and feeling less rested 
than the control sample. For the actigraphy outcomes, there were no differences between 
groups in the amount of sleep received each evening or how long it took to fall asleep. 
However, the control group appeared to spend significantly more time awake after sleep 
onset and demonstrated lower sleep efficiency than the GAD group. Specifically, healthy 
controls spent approximately 9 more minutes awake after sleep onset (mean = 37.96 
minutes, SD = 28.08 vs mean = 29.05, SD = 16.67) and slept approximately 3% less 
efficiently than GAD participants (mean = 83.17, SD = 11.13 vs 86.33, SD = 7.89).  
 Table 6 presents correlational analyses between subjective and objective sleep 
ratings. Both measures of subjective sleep were highly correlated with each other for the 
control group (r = .68, p < .001) and the GAD group (r = .60, p < .001). For the control 
group, self-reported ratings of sleep quality were significantly related to greater total 
sleep time, more efficient sleep, and lower sleep onset latency, while self-reported ratings 
of feeling rested were associated solely with greater total sleep time. In comparison, 
subjective sleep measures were not related to any of the objective sleep measures for the 
GAD group.  
Temporal Instability 
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 A unique aspect of time series or intensive longitudinal data is the ability to 
explore the temporal instability of time-varying phenomena, as extreme and frequent 
fluctuations in symptomology can be characteristic of psychopathology in and of itself.  
Temporal instability reflects not only high variability, but also low temporal dependency 
of data (Jahng, Wood, & Trull, 2008). To explore the temporal instability of sleep 
parameters and daily symptom ratings, mean square successive differences (MSSDs) 
were computed by squaring the difference between consecutive measurements. Since 
there were 14 days of monitoring in the current study, 13 square successive differences 
(SSDs) were computed in total and then a mean value was derived (MSSD). Since the 
MSSD is computed using successive change, the resulting value reflects both variability 
and temporal dependency and is thus recommended as the gold-standard for capturing 
temporal instability in both affective states and sleep behaviors (Sanchez-Ortuno, Carney, 
Edinger, Wyatt, & Harris, 2011; Suh et al., 2012). 
 Contrary to expectations, there were no between-group differences observed in 
temporal instability for any of the subjective sleep ratings (i.e., overall sleep quality, 
feeling rested upon awakening) or the actigraphy-derived sleep parameters (i.e., sleep 
onset latency, wake after sleep onset, sleep efficiency, total sleep time). However, the 
clinical sample demonstrated significantly greater instability than the control sample on 
daily depressed mood (t(15.97) = -2.30, p = .035; Figure 3), daily anxious mood (t(23.75) 
= -2.68, p = .013; Figure 4), anhedonia (t(27.12) = -3.42, p = .003; Figure 5), interference 
in functioning attributed to sleep (t(14.47) = -2.72, p = .016; Figure 6), and the 
cognition/alertness scale of the DISS (t(18.63) = -2.13, p = .047; Figure 7). Group 
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differences in temporal instability approached statistical significance for the 
sleepiness/fatigue (t(21.62) = -2.01, p = .057; Figure 8) and negative mood (t(25.34) = -
2.01, p = .055; Figure 9) scales of the DISS.  
 It is noteworthy that in comparison to healthy controls, participants with GAD 
experienced both higher overall levels of symptoms and greater day-to-day variability in 
the level of symptoms experienced. Moreover, there was less temporal dependency 
between days, suggesting that the levels of symptoms experienced at t-1 were not 
strongly correlated with the level of symptoms experienced at t.  
Statistical Analysis 
 To examine study aims, multi-level models (MLM), with daily symptoms nested 
within individuals, were constructed for each group. MLM is well equipped to handle 
data that is missing at random, which makes it an ideal approach for intensive 
longitudinal data (Fitzmaurice, Laird, & Ware, 2004). For the present study, adherence to 
daily symptom ratings was not predicted by group status, predictor variables, or outcomes, 
suggesting that data were indeed missing at random and that an MLM framework was 
appropriate. In addition, full maximum likelihood estimation was specified for analyses, 
which utilizes all available data to calculate between- and within-person level parameters 
and the associated standard errors. 
Models for the temporal analyses were built in a series of steps. Level 2 equations 
were specified to model between-person variability and level 1 equations were specified 
to model within-person variability. Accordingly, level 2 effects were estimated using 
each participant’s mean of the predictor variable across 14 days (i.e., one value) and level 
 32 
1 effects were estimated using each participant’s centered daily score (i.e., daily score – 
participant’s mean; 14 values), and therefore reflected an individual participant’s 
deviation from his or her mean. Next, lagged predictor variables were computed to 
examine associations among contemporaneous time-varying constructs. Time lags were 
computed for up to four days to determine peak significance of associations, where a one-
day lag reflected a predictor variable at t-1 predicting an outcome at t, a two-day lag 
reflected a predictor variable at t-2 predicting an outcome at t, and so on. Multiday lags 
were aggregated so that the lag represented a cumulative effect of the predictor variable 
over time (i.e., four-day lag predicting outcome t = Σ (predictor t-4, predictor t-3, predictor t-
2, predictor t-1].  
An autoregressive (AR[1]) repeated covariance type was specified to control for 
auto-correlations of residuals (Rovine & Walls, 2006). Autoregressive modeling treats 
the value of an outcome at each measurement occasion as a separate dependent variable 
and the prior measurement as the predictor, along with any other specified covariates, in 
the regression model. Time was represented by each day of the study, where day 1 of the 
study represented time 0, which anchored all level 2 effects at the first day of the study. 
Time was entered as both a fixed and random effect; the fixed effect of day estimated the 
mean association of time at the between-person level and the random effect estimated 
individual differences in the effect of time on the outcome of interest. The inclusion of 
time as a fixed effect in the model provided a more robust assessment of study aims since 
it prevents the model from estimating spurious temporal relationships between the 
predictor variables and the dependent variable. Therefore, time was retained as a fixed 
 33 
effect in subsequent models regardless of significance. Due to the lagged nature of the 
analyses, only the intercept and time were entered as random effects.  
Concurrent Associations Between Anxious and Depressed Moods 
 Anxious and depressed moods were concurrently associated for both the GAD 
group (B = .36, SE = .05, p < .001) and the control group (B = .30, SE = .04, p < .001), 
suggesting that individuals typically experienced greater depressed mood on days when 
they also felt greater anxiety.  
Does Anxious Mood Predict Later Sleep Disturbance?  
To evaluate whether anxious mood was associated with prospective sleep 
disturbance, level 1 and level 2 fixed effects were estimated for both subjective sleep 
ratings (i.e., overall sleep quality, how rested the participant felt upon awakening) and 
actigraphy sleep parameters (i.e., total sleep time, sleep onset latency, sleep efficiency, 
wake after sleep onset). The level 1 effect assessed the association between participants’ 
day-to-day deviations from their mean level of anxiety and day-to-day variation in sleep 
(i.e., do participants experience greater sleep disturbance following days that they 
experience higher-than-average anxiety?). The level 2 effect assessed the association 
between participants’ means levels of anxiety and sleep (i.e., do participants with higher 
levels of anxiety experience greater sleep disturbance than participants with lower levels 
of anxiety?).  
Table 7 displays the results for anxious mood predicting subsequent subjective 
sleep disturbance at different time lags for each group. For participants with GAD, there 
were no level 2 (between-person) effects observed for mean levels of anxious mood on 
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prospective sleep disturbance. Level 1 (within-person) results demonstrated that anxious 
mood was associated with subjective ratings of both overall sleep quality and feeling 
rested upon awakening at both a one- and two-day lag. However, the magnitude of the 
effect and statistical significance of the association between anxious mood and these 
subjective ratings were highest at a one-day lag, suggesting that when GAD participants 
experienced above-average levels of anxious mood, they rated their sleep quality as 
poorer and reported feeling less rested upon awakening the following morning. In 
comparison, there were no level 1 effects observed in the control group. There was a 
level 2 effect of anxious mood on ratings of feeling rested upon awakening, such that 
healthy controls who reported higher levels of mean anxious mood also reported feeling 
less rested. 
Table 8 displays the results for anxious mood predicting actigraphy sleep 
parameters at different time lags for each group. There were no level 2 (between-person) 
effects of anxious mood on sleep parameters for either group. For the GAD group, above-
average anxious mood at t-1was associated with lower sleep efficiency, more time spent 
awake after initial sleep onset, and less total sleep time at t. Among healthy controls, 
there was a negative linear temporal association for sleep onset latency, suggesting that 
these individuals experienced a decrease in the amount of time it took to fall asleep over 
the course of the study. 
To determine whether the significant associations observed between anxious 
mood at t-1 and sleep outcomes at t were independent of any associations with depressed 
mood, additional models were constructed for the GAD group. Mean levels of depressed 
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mood were included as a level 2 (between-person) effect and depressed mood values at t-
1, t-2, t-3, and t-4 were included as a level 1 (within-person) effect. Anxiety at t-1 
remained significantly associated with self-reported sleep quality at t (B = -.35, SE = .13, 
p = .008), subjective ratings of feeling rested at t (B = -.28, SE = .13, p = .026), total sleep 
time at t (B = -35.40, SE = 12.63, p = .006), and time spent awake after sleep onset at t (B 
= -4.50, SE = 2.26, p = .049); there was no effect of depressed mood at level 1 or level 2. 
Although the effect of anxious mood at t-1 on sleep efficiency at t was no longer 
significant once depressed mood was included in the model (B = -.02, SE = .01, p = .115), 
depressed mood was independently associated with sleep efficiency.  
Does Sleep Disturbance Predict Later Depressed Mood? 
To evaluate whether sleep disturbance was associated with depressed mood, level 
1 and level 2 fixed effects were estimated using both subjective sleep ratings (i.e., overall 
sleep quality, how rested the participant felt upon awakening) and actigraphy parameters 
(i.e., total sleep time, sleep onset latency, sleep efficiency, wake after sleep onset) as 
lagged predictor variables. Each model contained the four lagged predictor variables as 
level 1 (within-person) effects and the 14-day mean of the predictor variable as a level 2 
(between-person) effect. Based on previous analyses that demonstrated a significant 
effect of anxious mood at t-1 on sleep disturbance at t, anxious mood with a one-day lag 
was included as residual variance in the models estimating the effect of sleep disturbance 
at t-1 on depressed mood at t.  
Table 9 displays the results for subjective sleep disturbance predicting later 
depressed mood at different time lags for each group. Average sleep quality was 
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associated with depressed mood at the between-person level for both the GAD (B = -2.23, 
SE = .94, p = .025) and control group (B = -.16, SE = .04, p < .001), reflecting that 
individuals who reported better sleep quality relative to their cohort also reported lower 
levels of depressed mood at the onset of the study. For the GAD group, there was a 
significant level 1 (within-person) effect of sleep quality at t-1 on depressed mood at t, 
suggesting that on days when individuals in the GAD group rated the prior evening’s 
sleep quality as above-average, they also experienced lower levels of depressed mood (B 
= -.03, SE = .01, p = .048). The inverse relationship was observed for healthy controls, 
such that below-average levels of sleep quality across a two-day lag was associated with 
lower levels of depression (B = .04, SE = .02, p = .019). For the GAD group, there was a 
trend for the effect of feeling rested upon awakening at t-3 on depressed mood at t (B 
= .03, SE = .02, p = .052), indicating that the cumulative effect of feeling less rested than 
average over the course of three days was associated with higher levels of later depressed 
mood at t. For healthy controls, there was a level 2 (between-person) effect of feeling 
rested upon awakening (B = -.17, SE = .07, p = .020), reflecting that individuals who 
reported higher mean levels of feeling rested also reported higher levels of depression at 
the beginning of the study.  
For the actigraphy sleep parameters in the GAD group, there was a significant 
fixed effect of time spent awake after initial sleep onset at both level 1 and level 2 (see 
Table 10). These results suggest that at the between-person level, individuals with GAD 
who reported greater mean time spent awake after initial sleep onset also reported greater 
depressed mood at the onset of the study (B = -.05, SE = .02, p = .030). Additionally, 
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individuals with GAD who reported above-average time spent awake after sleep onset 
across a three-day lag also reported higher levels of depressed mood at t (B = .01, SE 
= .003, p = .033).  There were no significant associations observed between lagged 
actigraphy-assessed sleep parameters and depressed mood among healthy controls.  
Does Temperament Moderate the Associations Among Anxiety, Sleep Disturbance, 
and Depression? 
In order to determine whether the associations between anxiety and later sleep 
disturbance were moderated by temperament, specifically neuroticism and negative 
affectivity, cross-level interaction effects were computed. Each temperament predictor 
was group-mean centered and was added to the model to estimate the level 2 (between-
person) effect of the variable. Then equations reflecting the interactions between the level 
2 temperament predictor and the level 1 (within-person) lagged anxious mood predictors 
were added to the multilevel model. To interpret the interaction effect, simple slope tests 
were conducted (Jaccard & Turrisi, 2003).  
  For the GAD sample, there was no level 2 effect or cross-level effects of 
neuroticism or negative affectivity on lagged anxious mood in the prediction of self-
reported ratings of sleep quality. In the model predicting subjective ratings of feeling 
rested upon awakening, the interaction between neuroticism and anxious mood at t-1 was 
significant (B = -.06, SE = .03, p = .033; Figure 10). For the sleep parameters assessed via 
actigraphy, the only significant cross-level interaction was between negative affectivity 
and lagged anxious mood in the prediction of sleep onset latency (B = 1.68, SE = .42, p 
< .001; Figure 11). However, a similar trend was observed for the interaction between 
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neuroticism and lagged anxious mood at t-1 on sleep onset latency (B = 1.57, SE = .87, p 
= .074; Figure 12), as well as the interaction between negative affectivity and lagged 
anxious mood at t-1 on sleep efficiency (B = -.002, SE = .001, p = .063; Figure 13). These 
results suggest that the effect of anxious mood on later sleep disturbance is strongest for 
individuals higher in neuroticism and negative affectivity (i.e., one SD above group 
mean). For healthy controls, there were no cross-level interaction effects between 
temperament and lagged anxious mood on later sleep disturbance as assessed by either 
self-report or actigraphy. Temperament was also not associated with sleep disturbance as 
a level 2 (between-person) predictor. 
To evaluate whether temperament moderated the association between sleep 
disturbance and later depressed mood, cross-level interactions effects were computed in 
the same manner as described above. For participants with GAD, there was a trend 
toward a cross-level effect of neuroticism and subjective sense of feeling rested upon 
awakening at t-1 (B = -.02, SE = .01, p = .072; Figure 14) on depressed mood at t. Both 
neuroticism (B = -.001, SE = .001, p = .028; Figure 15) and negative affectivity (B = -.01, 
SE = .0003, p = .022; Figure 16) moderated the effect of sleep onset latency at t-1 on 
depressed mood at t. Negative affectivity also moderated the effect of time spent awake 
after sleep onset at a two-day lag (B = -.001, SE = .001, p = .022; Figure 17) and the 
effect of total sleep time at a three-day lag (B = .001, SE = .0003, p = .013; Figure 18) on 
daily depressed mood. These cross-level interactions reflect that for the GAD group, the 
effect of sleep disturbance on later depressed mood is strongest for individuals higher in 
neuroticism and negative affectivity.   
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 Among healthy controls, significant cross-level interactions were observed for 
neuroticism and self-reported sleep quality at t-2 (B = .01, SE = .003, p = .012; Figure 19), 
as well as neuroticism and subjective rating of feeling rested upon awakening at t-1 (B 
= .01, SE = .003, p = .002; Figure 20), on later depressed mood. Similarly to the 
associations observed in the clinical sample, lagged sleep disturbance exerted the 
strongest effect on later depressed mood for healthy individuals with above-average 
levels of neuroticism.   
Do Dysfunctional Beliefs About Sleep or Sleep-Related Safety Behaviors Moderate 
the Associations Among Anxiety, Sleep Disturbance, and Depression? 
 In order to explore whether levels of dysfunctional beliefs about sleep or sleep-
related safety behaviors, both assessed at baseline, moderated the lagged associations 
between anxiety and later depressed mood, cross-level interaction effects were computed 
and added to the multilevel model.  
 For the GAD group, there was a significant cross-level interaction between 
anxious mood at t-4 and dysfunctional beliefs about sleep on self-reported rating of 
feeling rested upon awakening at t (B = -.14, SE = .05, p = .007; Figure 21); anxious 
mood at t-1 and dysfunctional beliefs about sleep on subjective ratings of sleep quality at 
t (B = -.20, SE = .10, p = .044; Figure 22); and, anxious mood at t-3 and dysfunctional 
beliefs about sleep on sleep efficiency at t (B = -.02, SE = .01, p = .048; Figure 23). With 
regard to sleep-related safety behaviors, there was a significant cross-level interaction 
between anxious mood at t-4 and sleep-related safety behaviors on self-reported rating of 
feeling rested upon awakening at t (B = -.01, SE = .01, p = .042; Figure 24). A trend was 
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observed for the cross-level interaction between anxious mood at t-1 and sleep-related 
safety behaviors on amount of time spent awake after initial sleep onset at t (B = -.38, SE 
= .21, p = .079; Figure 25). These findings suggest that the effect of lagged anxious mood 
on subsequent sleep disturbance is strongest among GAD participants who also report 
higher levels of dysfunctional beliefs about sleep and engage in more sleep-related safety 
behaviors. For the control group, there were no cross-level interaction effects between 
either dysfunctional beliefs about sleep or sleep-related safety behaviors and sleep 
disturbance as assessed by self-report or actigraphy, and neither baseline predictor was 
associated with sleep disturbance as a level 2 effect.  
 For the association between sleep disturbance and depressed mood in the GAD 
group, there was a trend toward a moderation effect of dysfunctional beliefs about sleep 
on both total sleep time at t-4 (B = .002, SE = .001, p = .081; Figure 26) and subjective 
ratings of feeling rested upon awakening at t-4 (B = -.02, SE = .01, p = .065; Figure 27) in 
the prediction of depressed mood at t. In the control group, significant cross-level 
interactions were observed between dysfunctional beliefs about sleep and time spent 
awake after sleep onset at t-3 (B = .01, SE = .002, p = .006; Figure 28), as well as 
subjective ratings of feeling rested upon awakening at t-3 (B = -.05, SE = .02, p = .031; 
Figure 29), on depressed mood at t. Across both groups, higher levels of dysfunctional 
beliefs about sleep were associated with a stronger impact of lagged sleep disturbance on 
current depressed mood. Safety-related behaviors, on the other hand, did not moderate 
any of the associations between sleep disturbance and later depressed mood for either 
group.  
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Discussion 
 The primary aim of the present study was to explore the temporal relationships 
between symptoms of anxiety, depressed mood, and sleep disturbance at both the within-
person and between-person level. The study improved on prior studies of temporal 
patterns of anxious and depressed mood in GAD in several important ways. First, the 
present study utilized EMA procedures, which confer the advantage of time-stamped 
entries over daily diary studies and collected multiple ratings throughout the day that 
were then averaged to control for any diurnal effects on mood. Participants completed 
daily ratings of sleep satisfaction and also wore actigraphs, which facilitated the 
comparison of temporal associations with both subjective and objective measures of sleep. 
The present study also assessed study aims in both a clinical sample and a control group 
to ascertain whether observed temporal relationships were specific to individuals with 
GAD or also present in healthy controls.  
Sleep Disturbance 
 Compared to healthy controls, individuals with GAD reported greater sleep 
disturbance across all domains and more daytime dysfunction related to sleep difficulty at 
baseline. Throughout the 14-day study, GAD individuals also reported more sleep 
disturbance on a daily basis as reflected by lower ratings of sleep quality and reports of 
feeling less rested upon awakening. However, their subjective experience of sleep 
disturbance did not converge with actigraphy-derived sleep parameters. These findings 
are consistent with prior studies that have found weak relationships between objective 
and subjective sleep data in individuals with insomnia or mood disturbances (e.g., 
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Mayers et al., 2003; Means, Edinger, Glenn, & Fins, 2003). It has also been suggested 
that fatigue, a daytime symptom of insomnia, is more of a subjective sleep complaint than 
an objective finding in patients with depressive disorders (Dauvilliers, Lopez, Ohayon, & 
Bayard, 2013). 
Contrary to expectations, between-group differences in objective sleep 
disturbance (i.e., wake after sleep onset and sleep efficiency) were indicative of greater 
sleep disturbance in healthy controls. It is possible that these differences, while 
statistically significant, do not reflect clinically meaningful differences, although at least 
one other study found that healthy adults who denied any sleep problems demonstrated 
poorer sleep quality as assessed by actigraphy than those who identified as poor sleepers 
(McCrae et al., 2005). Unfortunately, there is a paucity of studies directly comparing 
objective and subjective sleep measures in individuals with anxiety disorders generally 
and no known studies in adults with GAD specifically, which limits the context in which 
these findings may be interpreted.  
Nevertheless, the absence of objective sleep impairment in the GAD group 
suggests that these individuals experience sleep disturbance and associated daytime-
interference based on variables that are not captured by more objective assessments of 
sleep (i.e., actigraphy). Qualitative data collected by Harvey and colleagues (2008) on the 
subjective meaning of sleep quality in insomnia and normal sleeper groups found that 
individuals with insomnia listed more required criteria for rating sleep as good quality. 
Although both groups reported fatigue upon awakening or throughout the day, nighttime 
awakenings, and sleep onset latency as the most important factors in their subjective 
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assessment of sleep quality, the insomnia group also listed motivation to get up in the 
morning and feeling alert, clear-headed, and able to concentrate throughout the day as 
critical aspects of sleep quality. Given that a lack of motivation and cognitive impairment 
(e.g., memory, processing speed, concentration) are commonly associated with 
depression and anxiety, it is not surprising that GAD participants in the present study 
rated their subjective sleep quality as poor. These findings are bolstered by other studies 
that have demonstrated that perceptions of sleep quality in individuals with insomnia are 
most closely related to daytime functioning and are not accounted for by quantitative 
sleep assessments or demographic factors (Ustinov et al., 2010).  
It is also common for patients with insomnia to misperceive their sleep as more 
impaired relative to objective measures, and this discrepancy appears to be most strongly 
related to worry, selective attention to sleep-related threats (e.g., noise), and the presence 
of brief awakenings (Harvey & Tang, 2012). Other studies have found that while worry is 
not associated with specific self-reported sleep parameters (e.g., sleep onset latency, 
wakefulness after sleep onset), it does appear to predict subjective ratings of interference 
and distress associated with sleep disturbance in individuals with insomnia (Carney, 
Harris, Moss, & Edinger, 2010b; O'Kearney & Pech, 2014; Takano, Iijima, & Tanno, 
2012). In a study comparing patients with GAD to healthy controls, emotion 
dysregulation was found to mediate the relationship between GAD and subjective sleep 
disturbance independently from the effect of comorbid diagnoses of depression or 
additional anxiety disorders (Tsypes, Aldao, & Mennin, 2013).  
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Although few studies have compared objective and subjective sleep indices in 
anxiety disorders, findings from the insomnia and depression literature provide strong 
evidence that the subjective experience of sleep disturbance may be distinct from 
objective sleep measures. Additionally, subjective sleep disturbance appears to be 
strongly tied to both dissatisfaction with daytime functioning (e.g., fatigue, alertness) and 
worry, which may represent a mutually reinforcing relationship that perpetuates distress 
about sleep.  
Affective Instability 
 In comparison to healthy controls, individuals with GAD demonstrated 
significantly more variability and less temporal dependency in their day-to-day ratings of 
anxious and depressed mood, anhedonia, sleep-related interference, and alertness. 
Although some disorders are characterized by temporal instability of affect, such as 
borderline personality disorder, anxiety and depressive disorders are most often 
conceptualized as pervasive affective states. However, results from the present study 
suggest that symptoms fluctuate significantly on a daily basis and that an individual’s 
level of symptoms on a given day may not be similar to the prior day’s level of the same 
symptom. Intolerance of uncertainty is considered a defining feature of GAD, so it is 
possible that the distress associated with the disorder is tied not only to the average level 
of anxiety experienced, but also to the unpredictability of which days will be 
characterized by above-average levels of anxiety (Gentes & Ruscio, 2011).  
 Prior research has shown that insomnia is often characterized by night-to-night 
instability (Buysse et al., 2010; Suh et al., 2012), and that this instability may be more 
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pronounced when symptoms of insomnia are related to another mental disorder (Sanchez-
Ortuno et al., 2011). Therefore, it is surprising that there were no differences between the 
control and GAD groups in temporal instability of either objective or subjective sleep 
disturbance. Given the small sample sizes, the degree of between-subject temporal 
instability in measures of sleep may have eclipsed any between-group differences. 
Temporal Associations Between Anxiety and Sleep 
Consistent with hypotheses, above-average levels of anxious mood at t-1 were 
predictive of poorer self-reported sleep quality and feeling less rested at t in participants 
with GAD. This relationship was moderated by both neuroticism and dysfunctional 
beliefs about sleep, such that the effect of anxious mood on subsequent subjective sleep 
disturbance was strongest in individuals with above-average levels of these baseline 
covariates. Dysfunctional beliefs about sleep reflect concern over meeting specific sleep 
requirements (e.g., getting 8 hours of sleep) and worry about the consequences of 
insomnia the following day, which puts considerable pressure on the individual to fall 
asleep and often produces a paradoxical effect. Prior studies have demonstrated that 
anxious cognitive arousal prior to bedtime is associated with both subjective and 
objective assessments of delayed sleep onset (Tang & Harvey, 2004; Wicklow & Espie, 
2000), so it is possible that higher-than-average levels of anxiety throughout the day 
interfere with sleep onset, which is especially distressing for individuals who tend to 
overestimate the effect of sleep quality on their functioning the following day. These 
results are supported by a recent cross-sectional comparison of patients with insomnia to 
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healthy controls matched in age and sex that found that the impact of neuroticism on 
insomnia was mediated by dysfunctional beliefs about sleep (Chauvin et al., 2015). 
An investigation of “folk theories” about the causes of insomnia conducted by 
Harvey and colleagues (2013) found that individuals most often attributed their insomnia 
to emotions (e.g., stress, anxiety, excitement), thinking patterns (e.g., can’t shut off 
thoughts), and sleep-related emotions (e.g., stress or anxiety about not falling asleep). If 
emotionality is perceived as a threat to sleep, it is not surprising that GAD participants in 
the current study who were both higher in neuroticism (and therefore more likely to 
experience negative affect and view themselves as unable to cope with stress) and 
overvalued the causal relationship between sleep and daytime functioning would be most 
affected by experiencing above-average anxiety on a particular day. This finding is 
consistent with prior research that has demonstrated that while cognitive and somatic 
arousal at bedtime are significant predictors of transient insomnia, dysfunctional beliefs 
about sleep and worry are the most important factors for distinguishing chronic insomnia 
from transient insomnia (Yang, Lin, & Cheng, 2013). 
Elevated anxious mood at t-1 was also predictive of objective sleep disturbance at 
t as characterized by lower sleep efficiency, more time spent awake after sleep onset, and 
shorter total sleep time in the GAD group, although the association between lagged 
anxious mood and sleep efficiency was no longer significant when depressed mood was 
included in the multilevel model. There was a trend for a moderation effect of sleep-
related safety behaviors on the association between anxious mood at t-1 and time spent 
awake after sleep onset at t, which suggests that individuals who report engaging in 
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safety behaviors related to sleep (e.g., going to bed early to allow plenty of time to fall 
asleep) more frequently may be particularly motivated to do so on days that they 
experience above-average levels of anxiety, which then results in greater sleep 
disturbance.  
For healthy controls, there were no significant within-person temporal 
relationships between anxiety and sleep disturbance. Individuals who reported higher 
mean levels of anxious mood did report feeling less rested upon awakening in the 
morning on day 1 of the study, which is consistent with the within-person temporal 
association observed in GAD participants. In other words, healthy controls did not appear 
to experience day-to-day fluctuations in anxious mood that influence subsequent sleep 
disturbance, but there was a between-person effect that reflected a significant association 
between greater average anxiety and perceptions of sleep as less restorative.  
Temporal Associations Between Sleep and Depression 
 Consistent with hypotheses, the associations between subjective sleep disturbance 
and later depressed mood were significant among GAD participants at both the between-
person and within-person level. In other words, higher average ratings of self-reported 
sleep quality predicted lower levels of depression and above-average sleep quality on a 
particular evening predicted less depressed mood the following day. Healthy controls 
demonstrated the same between-person association between sleep quality and depressed 
mood as the GAD group (i.e., higher average ratings of sleep quality were associated 
with lower mean levels of depressed mood). These results are consistent with prior 
research demonstrating that self-reported sleep disturbance is commonly associated with 
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depression (e.g., Babson, Trainor, Feldner, & Blumenthal, 2010; Mayers et al., 2009; 
Mayers et al., 2003; Yaugher & Alexander, 2015), and that poor subjective sleep quality 
is predictive of low mood the following day in both depressed individuals and healthy 
controls (Bower et al., 2010). Surprisingly, below-average sleep quality across a two-day 
lag was associated with lower levels of depression in healthy controls. This finding may 
reflect an antidepressant effect of acute sleep deprivation, although such an effect is 
typically most pronounced in depressed individuals (McEwen & Karatsoreos, 2015; Wolf 
et al., 2016). It is also possible that in the context of the very low levels of depressed 
mood that were reported in the control group, this effect, albeit statistically significant, 
does not capture clinically meaningful temporal associations between subjective sleep 
disturbance and mood.  
With regard to objective sleep measures, greater time spent awake after sleep 
onset across a three-day lag was predictive of greater depressed mood in the GAD group, 
suggesting that a cumulative effect (i.e., more than one night) of objective sleep 
disturbance may be necessary to affect levels of depressed mood the following the day in 
GAD individuals. Neuroticism and negative affectivity did moderate the effect of 
objective sleep disturbance on subsequent depressed mood, consistent with study 
hypotheses and prior research supporting the role of neuroticism as a predisposing factor 
for both insomnia (Gurtman, McNicol, & McGillivray, 2014) and depression (Naragon-
Gainey, Gallagher, & Brown, 2013). There were no associations between objective 
measures of sleep disturbance and subsequent depressed mood in healthy controls, which 
may reflect greater overall stability in these constructs. The absence of an association 
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may also indicate a between-group difference in how objective sleep disturbance affects 
mood the following day in healthy controls; for example, Van mill and colleagues (2013) 
found that short sleep duration was only associated with impaired work performance in 
individuals with psychopathology. 
Although sleep-related safety behaviors did not moderate any of the relationships 
between sleep measures and later depressed mood, dysfunctional beliefs about sleep 
moderated the effect of the sleep disturbance on subsequent depressed mood in both 
GAD individuals and healthy controls. Since there was some evidence that sleep-related 
safety behaviors moderate the effect of anxious mood on objective sleep quality in the 
GAD group, it is possible that sleep-related safety behaviors exert a more indirect effect 
on later depressed mood. It is also possible that dysfunctional beliefs about sleep are 
simply more proximally related to the association between sleep disturbance and 
depressed mood. In a previous study that discriminated between perceived need to use 
safety behaviors and actual use of safety behaviors, only ratings of safety behavior utility 
were associated with insomnia symptoms (Hood, Carney, & Harris, 2011). In addition, 
greater change in dysfunctional beliefs about sleep during treatment for insomnia has also 
been found to be associated with greater symptom remission for both insomnia and 
depression, further supporting the importance of this construct as a perpetuating or 
maintaining factor (Ashworth et al., 2015; Eidelman et al., 2016; Harvey et al., 2015). 
The questionnaire that assesses dysfunctional beliefs about sleep includes items 
such as, “when I feel irritable, depressed, or anxious during the day, it is mostly because I 
did not sleep well the night before,” so that the same interpretation bias may be present in 
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the reverse direction. Research suggests that negative cognitive biases are associated with 
depressive symptoms (Duque & Vazquez, 2015; Korn, Sharot, Walter, Heekeren, & 
Dolan, 2014; Wisco & Nolen-Hoeksema, 2010) and dysfunctional beliefs about sleep 
may represent a specific negative cognitive bias regarding the relationship between sleep 
and functioning. Consistent with this hypothesis, a recent study of undergraduates found 
that poor sleep quality was uniquely associated with enhanced memory for negative 
stimuli and a deficit in sustained attention to non-emotional stimui (Gobin, Banks, Fins, 
& Tartar, 2015). Taken together, these findings support prior research that has suggested 
that individuals with insomnia engage in ineffective cognitive control strategies at 
bedtime that results in difficulty down-regulating negative mood states the following day 
(Schmidt, Harvey, & Van der Linden, 2011).  
Clinical Implications  
 Findings from the present study may have important clinical implications. First, it 
provided insight into the naturalistic patterns of fluctuations in mood in individuals with 
GAD and either current or past history of depressed mood. It also characterized 
differences in subjective and objective sleep disturbance in adults with GAD complaining 
of insomnia compared to good sleeper, healthy controls. Although GAD individuals’ 
subjective perceptions of sleep disturbance were not correlated with objective sleep 
parameters, time-lagged multilevel analyses revealed that anxious mood predicted both 
subjective and objective sleep disturbance. These findings suggest that clinical 
interventions that target anxiety may be more effective at reducing sleep disturbance than 
interventions geared toward the treatment of insomnia. Moreover, to the extent that an 
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intervention is able to modify temperamental risk factors, such as neuroticism and 
negative affect, it may be possible to significantly attenuate the negative effect of anxiety 
on sleep. There is also some evidence from the present study to suggest that directly 
targeting dysfunctional beliefs about sleep during treatment may similarly reduce 
depressive symptoms through attenuation of the effect of sleep disturbance on subsequent 
depressed mood. 
Study Limitations and Directions for Future Research 
 Results from the present study should be interpreted in the context of several 
limitations. First, it was not possible to assess whether sleep disturbance mediated day-to-
day variation in anxious and depressed mood. Although the present study was able to 
identify temporal associations among time-varying variables, it was not able to 
definitively infer causal relationships amongst them or provide insight into why the 
observed temporal relationships exist. The inclusion of both subjective and objective (i.e., 
actigraphy) measures of sleep disturbance improves on previous studies that relied on 
only method, but even actigraphy is not fully objective; the scoring algorithms utilize the 
participant’s reported bedtime and waketime to calculate sleep parameters. The study 
samples, while well matched in sex, were predominantly female, which limits some of 
the generalizability of study findings. For the GAD sample, comorbid diagnoses of 
additional anxiety disorders were allowed provided that GAD was primary, which 
strengthens external validity, but also limits the ability to draw conclusions about whether 
the observed associations are specific to GAD or anxiety disorders more generally. Lastly, 
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although the use of brief, face-valid items facilitates compliance with EMA procedures, it 
may be desirable to utilize longer measures of mood that are validated.  
 Future research should explore the significance of affective instability in 
individuals with GAD and other anxiety disorders, and assess whether instability 
uniquely contributes to distress above and beyond mean levels of dysregulation. Even 
though multilevel modeling substantially magnifies the power of analyses, it will be 
important to replicate these findings in larger samples with more equitable sex ratios. 
Visual inspection of variability figures that suggest that some individuals experience 
more affective instability than others, and it may be informative to utilize sub-classes 
within clinical and control samples to determine whether variability is an important 
within-person predictor of symptomatology. Although the present study did assess 
moderation effects using baseline covariates, future studies should incorporate the 
assessment of concurrent moderators to facilitate more nuanced understanding of 
temporal associations. Finally, it will be important to assess the temporal associations in 
the context of treatment, which will also provide greater insight into the casual 
mechanisms driving these observed relationships.  
Conclusion 
 Sleep is a complex physiological process that intersects with affective states, such 
as anxious or depressed mood, in dynamic and multifaceted ways. For example, sleep 
deprivation can precipitate, exacerbate, or attenuate negative mood states (Wiebe, 
Cassoff, & Gruber, 2012). Results from the present study provide new insight into the 
associations between daily symptoms of sleep disturbance, anxiety, and depressed mood. 
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These findings emphasize the importance of concurrent assessment of both subjective 
and objective sleep disturbance, as objective sleep impairment appears to be only 
peripherally related to self-reported insomnia symptoms in individuals with GAD. In the 
context of recent research demonstrating that the presence of comorbid anxiety and 
depressive disorders does not negatively impact treatment outcomes for insomnia (e.g., 
Belanger et al., 2016; Hamoen, Redlich, & de Weerd, 2014), the present study provides a 
strong rationale for explicitly targeting sleep disturbance during treatment of emotional 
disorders.  
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Table 1. Demographic characteristics for each group.  
 
  Control   GAD    
Statistic 
   (n = 15)    (n = 15)   
M SD M SD t p-value 
Age 27.07 8.34 28.93 9.75 -0.56 0.58 
Principal Diagnosis CSR 5.27 .80  -- --    
Comorbid Diagnoses 1.20 .86  -- --    
 n %  n %  χ2 p-value 
Sex       0.16 0.69 
     Female 10 66.7  11 73.3    
     Male 5 33.3  4 26.7    
Ethnicity       0.83 0.36 
     Hispanic or Latino 4 26.7  2 13.3    
     Non-Hispanic or Latino 11 73.3  13 86.7    
Race       2.85 0.42 
     Caucasian 12 80  10 66.7    
     Black 0 0  2 13.3    
     Asian 2 13.3  1 6.7    
     Other 1 6.7  2 15    
Marital Status       10.91 0.012 
     Single 15 100  7 46.7    
     Married 0 0  5 33.3    
     Cohabitating 0 0  2 12.3    
     Divorced 0 0  1 6.7    
Employment       2.76 0.43 
     Full-time 6 40  4 26.7    
     Part-time 4 26.7  2 13.3    
     Student 5 33.3  8 53.3    
     Disability 0 0  1 6.7    
Education       12.8 0.012 
     High School Graduate 0 0  2 13.3    
     Partial College 1 6.7  4 26.7    
     College Graduate 7 46.7  7 46.7    
     Graduate School 7 46.7  2 13.3    
Handedness       0.37 0.54 
     Right 13 86.7  14 93.3    
     Left 2 13.3  1 6.7       
Note. GAD = Generalized Anxiety Disorder; CSR = Clinical Severity Rating. 
Table 2. Clinical characteristics for each group. 
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  Control   GAD    
Statistic 
   (n = 15)  (n = 15) 
M SD   M SD   t   p-value 
BDI 1.07 2.46 
 
21.13 10.74 -6.57 <.001 
BAI 2.13 2.80 
 
17.27 8.41 -6.61 <.001 
ASI 9.93 5.26 
 
27.40 12.43 -5.01 <.001 
STAI-T 48.45 4.16 
 
71.91 7.83 -10.24 <.001 
PSWQ 32.53 9.28 
 
70.87 7.76 -12.27 <.001 
PANAS-NA 11.20 1.52 
 
27.47 6.14 -9.96 <.001 
PANAS-PAa 36.93 4.32 
 
22.67 5.70 7.73 <.001 
NFFI-N 29.93 4.30 
 
42.06 3.69 -8.29 <.001 
WSI-E 10.67 6.64 
 
15.20 4.81 -2.14 .041 
WSI -I 19.67 12.81 
 
52.67 24.22 -4.66 <.001 
WSAS 1.07 1.80 
 
21.73 8.13 -8.85 <.001 
Q-LES-Q (%)a 84.40 10.68   47.86 16.29   7.27   <.001 
 
Note. GAD = Generalized Anxiety Disorder; BDI = Beck Depression Inventory; BAI = 
Beck Anxiety Inventory; ASI = Anxiety Sensitivity Index; STAI-T = State-Trait Anxiety 
Inventory, Trait Version; PSWQ; Penn State Worry Questionnaire; PANAS-NA = 
Positive and Negative Affect Schedule - Negative Affectivity; Positive and Negative 
Affect Schedule – Positive Affectivity; NFFI-N = NEO Five-Factor Inventory, 
Neuroticism Scale; WSI-E = Weekly Stress Inventory - Event Scale; WSI-I - Weekly 
Stress Inventory - Impact Scale; WSAS = Work and Social Adjustment Scale; Q-LES-Q 
= Quality of Life Enjoyment and Satisfaction Questionnaire.  
aFor these measures, higher scores are reflective of less impairment.  
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Table 3. Sleep measures for each group. 
 
  Control   GAD    
Statistic 
   (n = 15)  (n = 15) 
M SD   M SD   t   p-value 
ISI 2.46 1.64 14.67 3.56 -12.05 <.001 
FSS 22.93 7.57 41.40 10.25 -5.61 <.001 
SRBQ 22.86 16.70 52.80 13.28 -5.43 <.001 
DBAS 3.43 1.01 5.65 1.38 -5.04 <.001 
SHHC 29.86 10.99 44.40 10.74 -3.66 .001 
PSQI 
     Sleep Quality  0.47 0.50 1.87 0.34 -33.53 <.001 
     Sleep Latency  0.47 0.62 1.73 1.00 -15.60 <.001 
     Sleep Duration  0.27 0.44 1.13 1.09 -10.67 <.001 
     Sleep Efficiency  1.27 1.44 2.40 1.20 -8.76 <.001 
     Sleep Disturbances  0.80 0.40 1.60 0.61 -15.84 <.001 
     Sleep Medication  0.13 0.50 0.33 0.60 -3.72 <.001 
     Daytime Dysfunction  0.27 0.58 1.60 0.49 -25.56 <.001 
     Global Score  3.67 2.16 10.67 1.88 -9.47 <.001 
n % n % χ2 p-value 
MECS 0.22 0.48 
     Morning Type 2 12.3 1 6.70 
     Intermediate Type 12 80 14 93.00 
     Evening Type 1 6.7   0 0.00         
Note. GAD = Generalized Anxiety Disorder; ISI = Insomnia Severity Index; PSQI = 
Pittsburgh Sleep Quality Index; FSS = Fatigue Severity Scale; SRBQ = Sleep-Related 
Behaviours Questionnaire; DBAS = Dysfunctional Beliefs About Sleep Scale, Brief 
Version; SHHC = Sleep Habits and Hygiene Checklist; MECS = Morningness-
Eveningness Composite Scale.  
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Table 4. Daily symptom ratings for each group. 
 
  Control   GAD    
Statistic 
   (n = 15)    (n = 15)   
M SD M SD t p-value 
DISS Alert/Cognition (0-100) a 77.45 12.65 
 
51.96 13.12 
 
20.67 
 
<.001 
DISS Sleepiness/Fatigue (0-100) 21.69 14.12 
 
53.71 15.36 
 
-22.25 
 
<.001 
DISS Positive Mood (0-100)a 72.05 13.81 
 
45.48 14.58 
 
19.24 
 
<.001 
DISS Negative Mood (0-100) 9.81 9.61 
 
38.37 17.40 
 
-20.82 
 
<.001 
Anxious Mood (1-10) 1.51 0.74 
 
4.82 2.06 
 
-21.92 
 
<.001 
Depressed Mood (1-10) 1.14 0.37 
 
2.87 1.72 
 
-14.19 
 
<.001 
Anhedonia (1-10) 1.16 0.63 
 
4.07 2.51 
 
-15.89 
 
<.001 
Sleep-Related Interference (1-10) 1.75 1.27   4.88 2.53   -15.25   <.001 
 
Note. GAD = Generalized Anxiety Disorder; DISS = Daytime Insomnia Symptom Scale. 
Descriptive statistics were computed by first taking within-person means across all time 
points, and then computing descriptive statistics across participants.  
aFor these measures, higher scores are reflective of less impairment.  
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Table 5. Subjective and objective sleep data for each group. 
 
  Control   GAD    
Statistic 
   (n = 15)    (n = 15)   
Subjective Ratings M SD  M SD  t  p-value 
Sleep Qualitya 3.79 0.84 
 
2.95 0.80 
 
10.37 
 
<.001 
Rested Upon Awakeninga 3.55 0.85 
 
2.36 0.90 
 
13.74 
 
<.001 
Actigraphy Parameters M SD  M SD  t  p-value 
Sleep Onset Latency (mins) 23.07 33.35  18.35 27.66  1.64  .103 
Total Sleep Time (mins) 390.76 94.83  389.18 89.77  0.17  .862 
Sleep Efficiency (%) 83.17 11.13  86.33 7.89  -3.32  .001 
Wake After Sleep Onset (mins) 37.96 28.08  29.05 16.67  3.93  <.001 
Note. GAD = Generalized Anxiety Disorder. Descriptive statistics were computed by first 
taking within-person means across all time points, and then computing descriptive 
statistics across participants.  
aFor these measures, higher scores are reflective of less impairment.  
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Table 6. Correlation coefficients of subjective and objective sleep measures for each 
group. 
 
  Control   GAD  
 (n = 15)  (n = 15) 
  Sleep Qualitya 
Resteda 
  Sleep Qualitya 
Resteda 
Sleep Onset Latency -.18* -.03 .06 .06 
Wake After Sleep Onset -.07 -.06 .09 .13 
Sleep Efficiency .23** .12 -.01 -.03 
Total Sleep Time .28*** .32**   .05 .13 
 
Note. GAD = Generalized Anxiety Disorder. *p < .05; **p < .01; ***p < .001 (2-tailed). 
aFor these measures, higher scores are reflective of less impairment.  
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Table 7. Results of multilevel modeling analysis simultaneously predicting subjective sleep disturbance from anxious mood at 
four time lags for each group. 
      Control           GAD     
    (n = 15)       (n = 15)   
Dependent variable =  
Sleep Quality t B SE df t p   B SE df t p 
Between-Person 
      Average Anxious Mood -0.32 0.29 62.01 -1.11 .272 0.01 0.10 57.92 0.06 .957 
Within-Person 
      Day -0.01 0.02 57.13 -0.39 .701 -0.02 0.02 63.39 -0.69 .494 
      Anxious Mood t-1 -0.15 0.18 104.22 -0.84 .402 -0.43 0.11 110.37 -3.91 <.001 
      Anxious Mood t-2 -0.16 0.18 92.57 -0.91 .365 0.38 0.11 93.58 3.56 .001 
      Anxious Mood t-3 0.06 0.16 109.23 0.41 .686 -0.13 0.10 101.85 -1.31 .195 
      Anxious Mood t-4 0.00 0.09 148.21 0.05 .959 -0.01 0.06 146.50 -0.08 .934 
Dependent variable =  
Refreshed t B SE df t p   B SE df t p 
Between-Person 
      Average Anxious Mood -0.67 0.31 51.17 -2.18 .034 -0.11 0.10 52.32 -1.07 .291 
Within-Person 
      Day 0.01 0.02 63.99 0.60 .553 0.02 0.02 56.98 0.72 .478 
      Anxious Mood t-1 -0.10 0.16 110.28 -0.65 .515 -0.37 0.11 105.86 -3.39 .001 
      Anxious Mood t-2 0.00 0.15 110.33 0.01 .995 0.24 0.11 94.55 2.28 .025 
      Anxious Mood t-3 0.02 0.14 108.37 0.15 .878 -0.16 0.10 98.53 -1.55 .124 
      Anxious Mood t-4 0.02 0.09 149.69 0.21 .837   0.07 0.06 146.26 1.08 .282 
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Note. GAD = Generalized Anxiety Disorder; B = unstandardized coefficient; SE = standard error; df = degrees of freedom; t = 
t statistic; p = p-value. 
Table 8. Results of multilevel modeling analysis simultaneously predicting objective sleep disturbance from anxious mood at 
four time lags for each group. 
      Control           GAD     
    (n = 15)       (n = 15)   
Dependent variable =  
Sleep Efficiency t B SE df t p   B SE df t p 
Between-Person 
      Average Anxious Mood -0.02 0.05 52.48 -0.33 .746 0.01 0.01 76.36 0.89 .378 
Within-Person 
      Day 0.00 0.00 55.89 1.33 .188 0.00 0.00 62.33 0.70 .488 
      Anxious Mood t-1 0.00 0.02 117.29 0.08 .934 -0.02 0.01 127.35 -2.23 .028 
      Anxious Mood t-2 0.02 0.02 119.73 0.92 .361 0.01 0.01 89.38 1.29 .200 
      Anxious Mood t-3 -0.02 0.02 115.39 -1.17 .246 0.00 0.01 115.86 -0.07 .948 
      Anxious Mood t-4 0.01 0.01 150.92 0.70 .486 0.00 0.01 149.30 -0.14 .892 
Dependent variable =  
Sleep Onset Latency t B SE df t p   B SE df t p 
Between-Person 
      Average Anxious Mood -4.04 10.57 52.18 -0.38 .704 -0.36 2.95 64.32 -0.12 .904 
Within-Person 
      Day -1.93 0.86 62.78 -2.25 .028 -1.05 0.72 59.88 -1.47 .147 
      Anxious Mood t-1 1.85 5.83 113.24 0.32 .752 5.24 3.28 121.26 1.60 .113 
      Anxious Mood t-2 -4.85 5.65 113.80 -0.86 .393 -3.33 3.13 105.70 -1.06 .290 
      Anxious Mood t-3 1.66 5.17 110.53 0.32 .748 -0.71 3.02 113.54 -0.23 .816 
      Anxious Mood t-4 -1.01 3.55 152.03 -0.28 .777 1.18 1.88 154.60 0.63 .529 
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Dependent variable =  
Wake After Sleep Onset t B SE df t p   B SE df t p 
Between-Person 
      Average Anxious Mood 3.91 11.22 57.94 0.35 .729 1.46 1.71 70.16 0.85 .396 
Within-Person 
      Day 0.16 0.83 70.71 0.19 .853 0.59 0.45 44.31 1.32 .195 
      Anxious Mood t-1 0.16 6.21 118.02 0.03 .979 -4.05 2.05 123.73 -1.98 .050 
      Anxious Mood t-2 -6.58 6.02 113.83 -1.09 .276 2.51 2.02 90.53 1.24 .218 
      Anxious Mood t-3 6.53 5.50 118.19 1.19 .238 -1.31 1.91 113.49 -0.68 .495 
      Anxious Mood t-4 -0.92 3.54 151.34 -0.26 .795 0.16 1.08 148.91 0.15 .880 
Dependent variable =  
Total Sleep Time t B SE df t p   B SE df t p 
Between-Person 
      Average Anxious Mood -39.58 37.72 54.03 -1.05 .299 11.52 8.98 67.79 1.28 .204 
Within-Person 
      Day -0.32 2.88 69.85 -0.11 .912 1.27 2.20 63.13 0.58 .566 
      Anxious Mood t-1 -9.20 19.16 117.42 -0.48 .632 -35.72 11.42 122.41 -3.13 .002 
      Anxious Mood t-2 8.83 18.53 117.52 0.48 .635 16.94 11.22 89.97 1.51 .135 
      Anxious Mood t-3 -16.18 16.97 115.58 -0.95 .342 -1.97 10.63 111.88 -0.19 .854 
      Anxious Mood t-4 11.30 11.55 151.42 0.98 .329   0.82 6.03 150.67 0.14 .892 
Note. GAD = Generalized Anxiety Disorder; B = unstandardized coefficient; SE = standard error; df = degrees of freedom; t = 
t statistic; p = p-value. 
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Table 9. Results of multilevel modeling analysis simultaneously predicting depressed mood from subjective sleep disturbance 
at four time lags for each group. 
      Control           GAD     
    (n = 15)       (n = 15)   
Dependent variable =  
Depressed Mood t B SE df t p   B SE df t p 
Between-Person 
      Average Sleep Quality -0.16 0.04 35.69 -4.14 .000 -2.23 0.94 26.62 -2.37 .025 
Within-Person 
      Day 0.00 0.01 50.83 0.18 .859 0.05 0.09 14.69 0.51 .619 
      Sleep Quality t-1 0.00 0.01 95.45 -0.34 .733 -0.03 0.01 69.62 -2.02 .048 
      Sleep Quality t-2 0.04 0.02 82.17 2.39 .019 0.01 0.01 71.88 0.47 .638 
      Sleep Quality t-3 -0.05 0.03 73.28 -1.76 .083 0.02 0.01 56.02 1.42 .162 
      Sleep Quality t-4 0.01 0.01 81.74 1.08 .283 -0.01 0.01 84.57 -1.57 .120 
Dependent variable =  
Depressed Mood t B SE df t p   B SE df t p 
Between-Person 
      Average Rested -0.17 0.07 25.97 -2.47 .020 -0.64 0.66 36.70 -0.96 .342 
Within-Person 
      Day 0.01 0.01 41.69 1.04 .303 0.06 0.11 17.05 0.57 .577 
      Rested t-1 0.02 0.01 82.15 1.62 .110 0.02 0.01 80.99 1.39 .169 
      Rested t-2 -0.01 0.01 93.58 -0.44 .662 -0.02 0.01 101.24 -1.66 .100 
      Rested t-3 -0.01 0.01 78.03 -0.56 .579 0.03 0.02 84.63 1.97 .052 
      Rested t-4 0.00 0.00 21.95 0.63 .532   -0.02 0.01 93.64 -1.64 .105 
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Note. GAD = Generalized Anxiety Disorder; B = unstandardized coefficient; SE = standard error; df = degrees of freedom; t = 
t statistic; p = p-value. 
Table 10. Results of multilevel modeling analysis simultaneously predicting depressed mood from objective sleep disturbance 
at four time lags for each group. 
Dependent variable =  
Depressed Mood t B SE df t p   B SE df t p 
Between-Person 
      Average Sleep 
Efficiency 0.13 0.36 22.73 0.36 .722 -6.83 7.59 25.60 -0.90 .377 
Within-Person 
      Day 0.00 0.01 63.53 0.25 .803 0.04 0.11 17.31 0.33 .743 
      Sleep Efficiency t-1 0.00 0.00 92.93 1.27 .208 0.00 0.00 83.07 -0.59 .560 
      Sleep Efficiency t-2 0.00 0.00 114.90 0.33 .742 0.00 0.00 66.11 0.43 .668 
      Sleep Efficiency t-3 0.00 0.00 96.07 -1.01 .316 0.00 0.00 91.25 -1.52 .133 
      Sleep Efficiency t-4 0.00 0.00 137.64 0.52 .604 0.00 0.00 116.31 0.52 .607 
Dependent variable =  
Depressed Mood t B SE df t p   B SE df t p 
Between-Person 
      Average WASO 0.00 0.00 32.73 0.21 .838 -0.05 0.02 30.50 -2.27 .030 
Within-Person 
      Day 0.00 0.01 54.12 -0.31 .762 0.04 0.11 15.11 0.38 .711 
      WASO t-1 0.00 0.00 83.19 -1.66 .101 0.00 0.00 92.26 0.81 .419 
      WASO t-2 0.00 0.00 113.38 -0.08 .934 0.00 0.00 81.97 -0.97 .336 
      WASO t-3 0.00 0.00 88.98 0.27 .791 -0.01 0.00 81.02 2.17 .033 
      WASO t-4 0.00 0.00 109.67 0.56 .579 -0.01 0.00 99.65 -1.67 .099 
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Dependent variable =  
Depressed Mood t B SE df t p   B SE df t p 
Between-Person 
      Average Total Sleep 
Time 0.00 0.00 21.88 -0.80 .433 -0.01 0.01 21.79 -1.68 .108 
Within-Person 
      Day 0.00 0.01 58.44 -0.04 .968 0.03 0.10 17.03 0.34 .738 
      Total Sleep Time t-1 0.00 0.00 92.31 0.80 .427 0.00 0.00 74.33 -1.06 .291 
      Total Sleep Time t-2 0.00 0.00 91.25 1.56 .123 0.00 0.00 80.98 -0.74 .461 
      Total Sleep Time t-3 0.00 0.00 94.87 -1.87 .065 0.00 0.00 71.40 0.61 .545 
      Total Sleep Time t-4 0.00 0.00 119.51 0.84 .401 0.00 0.00 96.44 0.25 .807 
Dependent variable =  
Depressed Mood t B SE df t p   B SE df t p 
Between-Person 
      Average SOL 0.00 0.00 21.22 -1.71 .102 -0.02 0.02 18.03 -0.66 .518 
Within-Person 
      Day 0.00 0.01 52.15 0.15 .878 0.01 0.10 19.12 0.13 .902 
      SOL t-1 0.00 0.00 89.68 -1.72 .089 0.00 0.00 69.98 0.19 .851 
      SOL t-2 0.00 0.00 112.39 0.92 .362 0.00 0.00 78.63 -0.27 .786 
      SOL t-3 0.00 0.00 93.74 0.89 .378 0.00 0.00 67.28 0.21 .836 
      SOL t-4 0.00 0.00 109.31 -0.25 .805   0.00 0.00 82.18 0.93 .356 
Note. GAD = Generalized Anxiety Disorder; B = unstandardized coefficient; SE = standard error; df = degrees of freedom; t = 
t statistic; p = p-value; WASO = Wake After Sleep Onset. 
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Figure 1. Participant flow chart for healthy controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Completed Phone Screen 
n = 19 
Contacted  
n = 19 
Enrolled 
n = 17 
 
Currently in treatment (n = 1) 
Elevated sleep disturbance (n = 1) 
 
 
Completed Study 
n = 15 
 
Actigraph malfunctioned (n = 1) 
Unable to use SymTrend (n = 1) 
 
 67 
Figure 2. Participant flow chart for recruitment of clinical sample.  
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Figure 3. Variability across 14 days for daily average of depressed mood for the control 
group (a) and the GAD group (b). 
 
 
Note. GAD = Generalized Anxiety Disorder. Each individual’s data across 14 days are 
represented by a single line. 
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Figure 4. Variability across 14 days for daily average of anxious mood for the control 
group (a) and the GAD group (b). 
 
 
Note. GAD = Generalized Anxiety Disorder. Each individual’s data across 14 days are 
represented by a single line. 
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Figure 5. Variability across 14 days for end-of-day rating of anhedonia for the control 
group (a) and the GAD group (b). 
 
Note. GAD = Generalized Anxiety Disorder. Each individual’s data across 14 days are 
represented by a single line. 
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Figure 6. Variability across 14 days for end-of-day rating of interference in functioining 
attributed to sleep for the control group (a) and the GAD group (b). 
 
 
Note. GAD = Generalized Anxiety Disorder. Each individual’s data across 14 days are 
represented by a single line. 
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Figure 7. Variability across 14 days for daily average of alert/cognition scale of DISS for 
the control group (a) and the GAD group (b). 
 
 
Note. GAD = Generalized Anxiety Disorder; DISS = Daytime Insomnia Symptom Scale. 
Each individual’s data across 14 days are represented by a single line. 
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Figure 8. Variability across 14 days for daily average of fatigue/sleepiness scale of DISS 
for the control group (a) and the GAD group (b). 
 
 
Note. GAD = Generalized Anxiety Disorder; DISS = Daytime Insomnia Symptom Scale. 
Each individual’s data across 14 days are represented by a single line. 
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Figure 9. Variability across 14 days for daily average of negative mood scale of DISS for 
the control group (a) and the GAD group (b). 
 
 
Note. GAD = Generalized Anxiety Disorder; DISS = Daytime Insomnia Symptom Scale. 
Each individual’s data across 14 days are represented by a single line. 
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Figure 10. Cross-level interaction between anxious mood at t-1 and neuroticism on 
subjective rating of feeling rested upon awakening at t in the GAD group. 
 
 
Note. GAD = Generalized Anxiety Disorder; NFFI = NEO Five-Factor Inventory, 
Neuroticism Scale.  
aFor these measures, higher scores are reflective of less impairment.  
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Figure 11. Cross-level interaction between anxious mood at t-1 and negative affectivity 
on sleep onset latency at t in the GAD group. 
 
 
Note. GAD = Generalized Anxiety Disorder; NA = Positive and Negative Affect 
Schedule – Negative Affectivity.  
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Figure 12. Cross-level interaction between anxious mood at t-1 and neuroticism on sleep 
onset latency at t in the GAD group. 
 
 
Note. GAD = Generalized Anxiety Disorder; NFFI = NEO Five-Factor Inventory, 
Neuroticism Scale.  
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Figure 13. Cross-level interaction between anxious mood at t-1 and neuroticism on sleep 
efficiency in the GAD group. 
 
 
Note. GAD = Generalized Anxiety Disorder; NFFI = NEO Five-Factor Inventory, 
Neuroticism Scale.  
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Figure 14. Cross-level interaction between subjective rating of feeling rested upon 
awakening at t-1 and neuroticism on depressed mood at t in the GAD group. 
 
 
Note. GAD = Generalized Anxiety Disorder; NFFI = NEO Five-Factor Inventory, 
Neuroticism Scale.  
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Figure 15. Cross-level interaction between anxious mood at t-1 and neuroticism on 
depressed mood at t in the GAD group. 
 
Note. GAD = Generalized Anxiety Disorder; NFFI = NEO Five-Factor Inventory, 
Neuroticism Scale.  
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Figure 16. Cross-level interaction between sleep onset latency at t-1 and negative 
affectivity on depressed mood at t in the GAD group. 
 
 
Note. GAD = Generalized Anxiety Disorder; NA = Positive and Negative Affect 
Schedule – Negative Affectivity.  
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Figure 17. Cross-level interaction between wake after sleep onset at t-2 and negative 
affectivity on depressed mood at t in the GAD group. 
 
 
Note. GAD = Generalized Anxiety Disorder; NA = Positive and Negative Affect 
Schedule – Negative Affectivity.  
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Figure 18. Cross-level interaction between total sleep time at t-3 and negative affectivity 
on depressed mood at t in the GAD group. 
 
 
Note. GAD = Generalized Anxiety Disorder; NA = Positive and Negative Affect 
Schedule – Negative Affectivity.  
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Figure 19. Cross-level interaction between subjective sleep quality at t-2 and neuroticism 
on depressed mood at t in the control group. 
 
 
Note. NFFI = NEO Five-Factor Inventory, Neuroticism Scale.  
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Figure 20. Cross-level interaction between subjective rating of feeling rested upon 
awakening at t-1 and neuroticism on depressed mood at t in the control group. 
 
 
Note. NFFI = NEO Five-Factor Inventory, Neuroticism Scale.  
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Figure 21. Cross-level interaction between anxious mood at t-4 and dysfunctional beliefs 
about sleep on subjective rating of feeling rested upon awakening at t in the GAD group. 
 
Note. GAD = Generalized Anxiety Disorder; DBAS = Dysfunctional Beliefs About Sleep 
Scale.  
aFor these measures, higher scores are reflective of less impairment.  
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Figure 22. Cross-level interaction between anxious mood at t-1 and dysfunctional beliefs 
about sleep on subjective sleep quality at t in the GAD group. 
 
 
Note. GAD = Generalized Anxiety Disorder; DBAS = Dysfunctional Beliefs About Sleep 
Scale.  
aFor these measures, higher scores are reflective of less impairment.  
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Figure 23. Cross-level interaction between anxious mood at t-3 and dysfunctional beliefs 
about sleep on sleep efficiency at t in the GAD group. 
 
 
 
Note. GAD = Generalized Anxiety Disorder; DBAS = Dysfunctional Beliefs About Sleep 
Scale.  
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Figure 24. Cross-level interaction between anxious mood at t-4 and sleep-related 
behaviors on subjective rating of feeling rested upon awakening at t in the GAD group. 
 
Note. GAD = Generalized Anxiety Disorder; SRBQ = Sleep-Related Behaviors 
Questionnaire. 
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Figure 25. Cross-level interaction between anxious mood t-1 and sleep-related behaviors 
on time spent awake after sleep onset at t in the GAD group. 
 
 
Note. GAD = Generalized Anxiety Disorder; SRBQ = Sleep-Related Behaviors 
Questionnaire. 
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Figure 26. Cross-level interaction between total sleep time at t-4 and dysfunctional 
beliefs about sleep on depressed mood at t in the GAD group. 
 
 
Note. GAD = Generalized Anxiety Disorder; DBAS = Dysfunctional Beliefs About Sleep 
Scale.  
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Figure 27. Cross-level interaction between subjective rating of feeling rested upon 
awakening at t-4 and dysfunctional beliefs about sleep on depressed mood at t in the 
GAD group. 
 
 
Note. GAD = Generalized Anxiety Disorder; DBAS = Dysfunctional Beliefs About Sleep 
Scale.  
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Figure 28. Cross-level interaction between time spent awake after sleep onset at t-3 and 
dysfunctional beliefs about sleep on depressed mood at t in the control group. 
 
 
Note. DBAS = Dysfunctional Beliefs About Sleep Scale.  
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Figure 29. Cross-level interaction between subjective rating of feeling rested upon 
awakening at t-3 and dysfunctional beliefs about sleep on depressed mood at t in the 
control group. 
 
 
Note. DBAS = Dysfunctional Beliefs About Sleep Scale.  
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